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Introduction. Skin and skin structure infections (SSSI) are among the most 
frequent human bacterial infections and an increasing indication for 
antimicrobial treatment both in the hospital and in the outpatient setting. In 
1998, The U.S. Food and Drug Administration (FDA) classified SSSI as 
complicated (cSSSI) if it involves deep subcutaneous tissues, needs surgery 
in addition to antimicrobial therapy or affects a patient with severe co-
morbidities like diabetes. Presently, practically all new antimicrobials against 
Gram-positive bacteria are studied before licensing on patients with SSSI. 
FDA recommended in 2013 that in these studies, the early treatment 
response (within 48–72 hours after initiation of therapy) should be used as 
the primary outcome measure.  
The aims of this population based retrospective observational study were: 
(1) to assess the present characteristics and outcome of patients with cSSSI in 
low resistance area, (2) to analyse the factors associated with the time to 
clinical stability and to evaluate the association of early response to outcome, 
(3) to compare the microbiological aetiology and treatment practices between 
diabetics and nondiabetics, and (4) to compare the treatment practises of 
cSSSI between two cities with similar public health care structure and low 
incidence of antimicrobial resistance. 
 
Study population. The study population consisted of all adult residents 
from two cities with nearly equal size of population (Helsinki, Finland and 
the Gothenburg area, Sweden) who were treated in hospital because of cSSSI 
in 2008–2011. First patient selection from hospital databases with specific 
ICD10 codes revealed 3315 patients with SSSI, of which 460 cases were 
severe enough to meet the above FDA criteria for cSSSI. These 460 patients 
constituted the final analysis population of the study. 
 
Main results. In the final analysis population, bacteraemia was detected in 
13%, treatment failure in 38%, initial antibiotic treatment modification in 
39% but a switch to narrower-spectrum antibiotic treatment (streamlining) 
only in 5% of patients. Staphylococcus aureus (21%) and streptococci (16%) 
were the most common etiologies in monomicrobial infections. The overall 
mortality within 30 days was 4.1% and a recurrence within 12 months was 
experienced by 16% of patients.  
In study II (n=402), 59% of patients had clinical stability within 3 days. In 
multivariable analysis, late (≥4 days) clinical stability was statistically 
significantly associated with admission to ICU (OR 10.1, 95% CI 4.01–25.3), 
posttraumatic wound infection (OR 3.17, 95% CI 1.31–7.69), bacteraemia 
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(OR 3.09, 95% CI 1.36–7.02), surgical intervention after diagnosis (OR 2.64, 
95% CI 1.36–5.11), diabetes (OR 2.33, 95% CI 1.28–4.25) and initial broad-
spectrum antibiotic therapy (OR 3.03, 95% CI 1.43–6.40). Early stabilization 
(within 3 days) was associated with previous hospitalization (OR 0.47, 95% 
CI 0.22–0.99) and empirical antimicrobial therapy covering the initial 
pathogens (OR 0.38, 95% CI 0.18–0.80). Patients with clinical stability 
within 3 days were less likely to have treatment modifications and 
antimicrobial changes and had shorter hospital stay and antimicrobial 
treatment than those who stabilized later.  
In study III, after exclusion of patients with diabetic foot infection (DFI), 
there was no difference in the microbiological aetiology or initial 
antimicrobial treatment of cSSSI between diabetics and nondiabetics. Yet, 
diabetes was the only baseline characteristic associated with broad-spectrum 
antimicrobial use and long (≥17 days) antibiotic treatment duration.  
In study IV, patients in Helsinki, as compared to those in Gothenburg, 
were treated more often with antimicrobials with Gram-negative coverage (in 
initial treatment 96% versus 47%, p<0.001), had more treatment 
modifications (mean 4.3 versus 2.7, p<0.001) and longer median duration of 
antimicrobial therapy (29 days versus 12 days, p<0.001) and longer in-
hospital stay (17 days versus 11 days, p<0.001). During their hospital stay, 
57% of patients in Helsinki visited more than one department while in 
Gothenburg 85% of patients were treated in only one department. These 
observations were unlikely explained by the differences detected between the 
cities in the baseline and disease characteristics of the patients. 
 
Conclusions. In this population based real-life study, bacteraemia, clinical 
failures, recurrences and treatment modifications (other than streamlining) 
were more common than in previous non-population-based studies. The 
study observations suggest that time to treatment response depends on 
several baseline and disease related characteristics other than treatment 
related factors and that early treatment response was associated to better 
outcome. This study also suggests that diabetics without DFI, as compared to 
nondiabetics, are not different in the causative agents of cSSSI, but they were 
more exposed to antimicrobial therapy of inappropriate extended spectrum 
and long duration. Furthermore, this study revealed remarkable differences 
in the treatment and management of cSSSI between two Nordic cities. 
Importantly, the real-life observations of our study have detected several 
targets for antimicrobial stewardship. 
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The skin together with the subcutaneous tissue is the largest organ of the 
human body, accounting for 15–25% of the total body weight [1]. As the 
outermost layer of the body one of its main function is to serve as a physical 
barrier and to protect from an invasion of microbes [1]. The human skin is 
colonized by a variety of microorganisms, including bacteria, fungi, viruses 
and mites [2]. Most of those microbes of the normal flora are harmless or 
even beneficial and they may act as a competitive inhibitor of pathogenic 
microbes [2]. 
Skin and skin structure infection (SSSI) reflects an invasion of microbes, 
usually after damage to skin, and the causative inflammatory reaction in any 
of the three layers of skin – epidermis, dermis or subcutaneous tissue – or to 
fascia between subcutaneous tissue and muscle. SSSIs are usually classified 
according to the anatomical site of infection (Figure 1) but classifications by 
severity, purulence or microbial aetiology of infection have also been utilized 
[3,4]. Gram-positive aerobic cocci – particularly streptococci and 
Staphylococcus aureus – are the most common causative agents of SSSIs, 
but in complicated cases also Gram-negative rods and anaerobic bacteria are 
frequently detected [5-8]. 
SSSIs are among the most frequent human bacterial infections and 
antimicrobial treatment is increasingly used for them for both in the hospital 
and in the outpatient setting [9-14]. The mildest SSSIs can be treated without 
systemic antimicrobial therapy, either by topical treatment (e.g. local 
impetigo) or by incision and drainage (e.g. simple abscess) [4]. In the United 
States, the annual incidence of clinically diagnosed SSSI was calculated as 
496/10’000 inhabitants [11]. During a 7-year period totally 4’891’187 hospital 
admissions with a primary diagnosis of SSSI were identified in the U.S. [15]. 
In Finnish health care centers during 1998–2002, SSSIs were the sixth most 
common infection, accounting for 6% of all infection-related doctor’s 
appointments [16]. These figures have not been bypassed unseen by the 
medical industry and practically all new antimicrobial agents against Gram-
positive bacteria are currently studied in patients with SSSI before licensing. 
SSSI is generally regarded as complicated (cSSSI) if it involves deep 
subcutaneous tissues, needs surgery in addition to antimicrobial therapy or 
affects a patient with severe co-morbidities [17]. Our population-based 
survey was conducted in Helsinki and Gothenburg during 2008–2011, and 
the above criteria were utilized to find patients with cSSSI. Our objective was 
to evaluate the background and disease characteristics, treatment and 
outcome of cSSSIs in real-life population-based setup. High affinity to public 
health-care in the Nordic countries enabled the population-based approach 
with more comprehensive patient material, in contrast to clinical trials with 





2 REVIEW OF THE LITERATURE 
2.1 DEFINITIONS OF SSSI 
A skin and skin structure infection (SSSI) is an infection affecting skin 
and/or subcutaneous connective tissue. Several classification systems have 
been used to describe SSSIs but none of them is universally accepted [18]. In 
general, SSSIs can be classified to purulent or non-purulent infections and on 
the other hand by the depth of infection. Purulent SSSIs include folliculitis, 
furuncle, carbuncle, abscess and inflamed epidermoid cyst (Table 1) and non-
purulent SSSIs comprise, from the most superficial to the deepest infection, 
impetigo/ecthyma, erysipelas, cellulitis and necrotizing fasciitis (Table 1 and 
Figure 1). Although it may be anatomically incorrect infectious (necrotizing) 
myositis is often included in SSSIs. 
 
 
Table 1  Overview of the different skin and skin structure infections according to   
  anatomical site of infection (wound infections not included) [4]. 
 
Infection 
Infected structure or 











folliculitis hair follicle S. aureus topical antimicrobial 
furuncle 
hair follicle, dermis and 
subcutaneous tissue 
S. aureus 
incision and drainage 
(systemic antimicrobial [a]) 
carbuncle 




incision and drainage 
(systemic antimicrobial [a]) 
abscess any layer of the skin S. aureus 
incision and drainage 
(systemic antimicrobial [a]) 
inflamed 
epidermoid cyst 
epidermoid cyst normal skin flora 
incision and drainage 










impetigo superficial epidermis 
S. aureus and 
streptococci 
topical (or oral [b]) 
antimicrobial 
ecthyma deeper epidermis 




erysipelas [c] superficial dermis streptococci systemic antimicrobial 
cellulitis [c] 












surgical debridement and 
systemic antimicrobial 
[a] For patients with severely impaired host defenses or signs or symptoms of systemic infection 
[b] For patients with numerous lesions or in outbreaks affecting several people 
[c] In European countries, cellulitis and erysipelas are used often as synonyms 
 




Figure 1  Schematic picture of the skin and localization of the different types of non-  
  purulent infections. 
 
 
The skin consists of several layers (Figure 1) and structures each of which 
can be affected by an infection (Table 1). Evaluation of the depth of SSSI – 
particularly distinction between erysipelas and cellulitis – is not so clear-cut 
in practise, therefore clinicians often use the term erysipelas as a synonym to 
cellulitis, beyond the classic definition [19,20]. When compared to cellulitis, 
erysipelas affects only the superficial part of dermis and the skin lesion is 
slightly elevated and sharply demarcated from the surrounding unaffected 
skin [21]. In clinical practise, the distinction between erysipelas and cellulitis 
is usually not crucial since they have similar risk factors and mostly similar 
aetiology and treatment [4-6,22,23]. 
2.1.1 DEFINITIONS OF SSSI USED IN CLINICAL STUDIES AND 
GUIDELINES 
Initially for the purpose of clinical trials for new drugs for SSSIs, in 1998 The 
US Food and Drug Administration (FDA) divided SSSIs into two categories: 
Complicated (cSSSI) and uncomplicated (uSSSI, Table 2). SSSI was 
considered as complicated if it involves deeper soft tissue (e.g. fascia or 
muscle) or rectal area, requires significant surgical intervention or affects a 
patient with a significant underlying disease that complicates the treatment 
response [17]. Therefore, the umbrella of cSSSI covers a variety of infections 
sharing common microbiological features, such as infected ulcers and burns, 
major abscesses, deep subcutaneous infections and infections in diabetics or 
patients with vascular insufficiency. In contrast, simple abscesses, 





examples of uSSSIs. The disease process of SSSI is not rigid and uSSSI may 
escalate to cSSSI if not managed properly. 
A definition “acute bacterial skin and skin structure infection” (ABSSSI), 
was introduced in 2013 by the FDA in guideline on developing drugs for 
treatment of SSSI, and included cellulitis/erysipelas, acute wound infections 
and major skin abscesses with a minimum lesion surface area of 75 cm2 
(Table 2) [24]. For example, diabetic foot infections (DFI), deep 




Table 2 The characteristics of different classifications used in clinical trials of skin and 
 skin structure infections. 
Classification Characteristic Infections included in the classification 
uSSSI 
Superficial skin infections or 
infections that can be treated by 
incision and drainage alone 
Simple abscesses, impetigo, folliculitis, 
furuncles and superficial cellulitis 
cSSSI 
Skin infection that involves deeper 
soft tissue or rectal area, requires 
significant surgical intervention or 
affects a patient with significant 
underlying disease that complicates 
the response to treatment 
Infected ulcers and burns, major 
abscesses, deep subcutaneous infections 
and diabetic foot infection 
ABSSSI 
Bacterial skin infection, minimum 
lesion area 75 cm2 
Cellulitis/erysipelas, acute wound infection 
and major skin abscess 
uSSSI, uncomplicated skin and skin structure infection 
cSSSI, complicated skin and skin structure infection 
ABSSSI, acute bacterial skin and skin structure infection 
 
 
The Infectious Disease Society of America (IDSA) has retained the term 
“skin and soft tissue infection” (SSTI), a synonym to SSSI, in their 
nomenclature [4]. Particularly in the perspective of treatment, in their recent 
guideline IDSA classifies SSTIs into two broad categories, non-purulent and 
purulent and further identifies 10 different types of SSTIs (Table 1) [4]. 
A clinical management oriented classification of SSTI suggested by Eron 
et al includes four levels of severity: 1. Patients with no signs or symptoms of 
systemic toxicity or co-morbidities; 2. Patients that are systemically unwell 
with stable co-morbidities or systemically well but have a comorbidity that 
may complicate the course of disease; 3. Patients appear toxic (e.g. 
tachycardia, tachypnea or hypotension) or non-toxic but have unstable 
comorbidities that may delay response to therapy; 4. Patients with sepsis 
syndrome or life-threatening infection, e.g. necrotizing fasciitis [3]. In the 
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Eron classification cSSSIs are located in Classes 2–4. Marwick et al. modified 
the Eron classification by utilizing sepsis criteria and standardized early 
warning score (SEWS) in particular to separate severity classes 3 and 4 [25-
27]. SEWS scoring system includes following parameters: respiratory rate, 
blood oxygen saturation, body temperature, blood pressure, heart rate and 
level of consciousness [27]. 
The World Society of Emergency Surgery (WSES) used three categories in 
their recent guideline for the treatment of SSTI: Surgical site infections (SSI), 
non-necrotizing SSTIs and necrotizing SSTIs (NSTI) [28]. Non-necrotizing 
SSSIs usually involve the superficial layers of the skin (epidermis and 
dermis) and subcutaneous tissue, while necrotizing SSSIs most usually affect 
the deeper fascia and muscle [29]. In literature some terms of necrotizing 
SSSIs are also based either on anatomical site (necrotizing fasciitis of 
anogenital region, i.e. Fournier´s gangrene) or on microbiological aetiology 
(e.g. clostridial gas gangrene). 
Health-care associated infections (HAI), including SSIs, are important 
groups of SSSI. The Center for Disease Control and Prevention (CDC) divides 
health-care associated SSSIs into skin (skin and subcutaneous tissue) and 
soft tissue (fascia and muscle) infections [30]. When SSI is at issue, the 
former group constitutes superficial and the latter deep incisional SSIs, 
respectively [31]. The deepest of SSIs – organ space infections – are not 
SSSIs. 
In conclusion, SSSIs can be classified from many perspectives and no 
universally adopted classification system exists. Complicated SSSIs represent 
a heterogeneous group of disorders ranging from severe infection in a patient 
with no co-morbidities to relatively minor infection in patient with major co-
morbidities that may complicate treatment response. Although initially 
designed for the purpose of clinical trials, the umbrella term cSSSI used in 
this thesis is still valid and useful in the detection of the most severe forms of 
SSSIs [32]. In our studies the goal was to catch the patients with the most 
serious infection, therefore we did not exclude any severe entities (e.g. 




2.2 EPIDEMIOLOGY OF CSSSI 
2.2.1 INCIDENCE OF CSSSI 
Several studies have detected an increasing incidence of SSSIs and rate of 





hospital admissions for pneumonia has remained relatively constant [12]. 
Most recently, the annual incidence of clinically diagnosed SSSI in the United 
States was calculated as 496/10’000 [11] and hospital admissions due to SSSI 
increased from 1.6% (2005) to 2.0% (2011) of the total hospital admissions 
[15]. In contrast, Miller et al found the incidence of SSSI to been relatively 
constant among persons less than 65 years in the U.S. population during 
2005–2010 [33]. They detected the annual incidence of SSSIs around 
480/10’000, approximately two and ten-fold higher than the incidences of 
urinary tract infection and pneumonia in the same study population [33]. In 
the United Kingdom, three-fold increase was found in the annual hospital 
admissions due to abscess or cellulitis during 1990–2004 and up to four to 
five-fold higher hospitalization rate was detected in the oldest (≥85 years) 
patients in comparison to the younger age groups (15–44 years and 45–64 
years) – the annual hospitalization rates due to SSSI were 634/100’000 and 
123/100’000 among them in 2003–2004, respectively [13]. The incidence of 
SSSIs has been consistent with the reported increase of community-
associated methicillin-resistant S. aureus (CA-MRSA) infections [10,12]. 
In a European point-prevalence survey, SSSIs combined with bone and 
joint infections were the second most common indication of antimicrobial 
treatment after pneumonia and comprised 18% of the total antibiotic use 
[34]. In the U.K., a rise in the amount of antibiotic prescriptions for SSSI 
among out-patients was detected during 1991–2012 [14]. After pneumonia 
and intra-abdominal infections, SSSIs are the third most frequent cause of 
severe sepsis or septic shock, accounting for about 10% of all cases of septic 
shock [35-37]. SSIs are the most common HAI in U.S. affecting overall 1.9% 
of the patients after surgical procedure during 2006–2008 [38]. 
Due to heterogeneity of the disease entity and lack of population based 
studies the incidence of cSSSI in general population is largely unknown. 
Miller et al suggest the incidence of cSSSI to be as high as 20/1000 person 
years, yet their criteria for complication differed from the original FDA 
criteria [17,33]. 
2.2.2 RISK FACTORS OF CSSSI 
To the best of my knowledge, any case-control studies comparing patients 
with cSSSI to general population to evaluate risk factors specifically for cSSSI 
have not been made. However, in addition to diseases defining SSSI as 
complicated, case-control studies made in patients with cellulitis have 
detected several risk factors to skin infection: obesity, chronic leg oedema, 
prior saphenectomy, history of previous cellulitis, skin lesion as a possible 
site of bacterial entry and bacterial colonization of toe-webs as risk factors for 
cellulitis of the lower extremity [22,23,39,40]. The incidence of cellulitis 
increases with age [41]. In a Danish observational study, obesity was detected 
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as a risk factor for skin abscess in both sexes and for other types of SSSI in 
men [42]. 
Patients’ background characteristics (e.g. co-morbidities) have been 
evaluated in the observational studies of cSSSI. The most frequent 
comorbidities observed among patients with cSSSI have been diabetes 
mellitus (24%–35%) and peripheral vascular disease (PVD, 7%–21%) [43-
47]. Malignancy (4.0%–20% of patients with cSSSI), chronic renal disease 
(10%–17%), immunosuppression (3.5%–15%), intravenous drug abuse 
(2.3%–14%), chronic pulmonary disease (3.0%–13%), chronic liver disease 
(4.0%–12%), and congestive heart disease (3.7%–12%) have also been 
pointed out as usual comorbidities in patients with cSSSI [43-47]. 
In comparison to general population, patients with diabetes are more 
susceptible to variety of infectious diseases, have more community-based 
antibiotic prescriptions and increasing rates of hospitalizations due to 
infection, including SSSI [48-51]. Diabetes predisposes to the development of 
SSSI through multiple mechanisms. First, in vitro studies have shown that 
neutrophil function is reduced and that humoral immunity and antioxidant 
systems may be impaired in diabetes [52-54]. Second, due to peripheral 
polyneuropathy diabetics are prone to the development of foot ulcers, which 
offer a site of entry to pathogens. The lifetime risk for a diabetic patient to 
develop an ulcer is estimated to be as high as 25% [55]. Third, patients with 
diabetes have up to four-fold higher risk of developing PVD compared to 
patients without diabetes [56]. The combination of PVD and infection was 
observed to have a major impact on the healing rate of foot ulcer [57] and in 
another study PVD was an independent predictor of infection-related 
mortality [58]. 
Subcutaneous or intramuscular, instead of intravenous, injections are 
major risk factors for abscesses and SSSIs are the most common cause of 
hospital admission among intravenous drug users (IDU) [59,60]. In the U.K. 




2.3 DIAGNOSIS AND PATHOGENESIS OF CSSSI 
Typical presentation of a skin and skin structure infection incudes the four 
classical local signs of inflammation described in the first century by Celcus – 
calor, rubor, tumor and dolor (heat, redness, swelling and pain). A fifth local 
sign (fluor, discharge), systemic signs of inflammation (fever, tachycardia 
and tachypnea) and lymphangitis with inflammation of regional lymph nodes 
are also frequently present in cSSSI. Systemic signs may sometimes be 





SSSIs arise usually by a direct microbial invasion after a disruption of the 
skin surface and rarely by a haematogenous spread of microbes from a 
remote infection focus. The portal of entry of the microbes may be obvious, 
such as ulceration or trauma, or small and difficult to detect, or even not 
located in the site of SSSI. Compared to intact skin, breaks in the skin allow 
colonization with a broader range of microbes [2]. Clinically important, 
microbial colonization of damaged skin does not usually result in 
inflammation or infection and therefore is not an indication of antimicrobial 
treatment [32]. In the pre-antibiotic era, the most typical location of 
erysipelas was the face, but currently erysipelas most likely affects the lower 
extremity, wherein cSSSIs are also typically located [45,62]. 
In contrast to abscess with high microbial density, cellulitis is a 
paucibacillary infection, characterized by an intensive inflammatory 
response and more scattered microbial spread in the tissue [63]. Important 
from the point of therapeutic view, inflammation surrounding a collection of 
pus (e.g. abscess) is not regarded as a cellulitis [4]. Necrotizing fasciitis is an 
aggressive infection affecting usually the superficial fascia between the 
subcutaneous tissue and muscle, which allows the rapid spreading of the 
infection. Pain “out of proportion” and swelling beyond the area of apparent 
skin involvement and signs of systemic toxemia are the most distinctive 
features of necrotizing fasciitis [64]. Recognition of abscess – and especially 
necrotizing infection – is of paramount importance, since the primary 
treatment of these entities is surgical [28,64]. 
2.3.1 BIOMARKERS 
Eder et al. found PCT and CRP levels to be higher in patients with cSSSI than 
in patients with SSSI, median PCT levels 0.3 ng/ml versus 2.0 ng/ml and 
CRP 135 mg/l versus 263 mg/l, respectively [65]. In a study on group A 
streptococcal (GAS) skin infection, patients with invasive infection had more 
likely blood neutrophil percentages of above 80 (81% versus 48%) and higher 
CRP level (mean 205 mg/l versus 78 mg/l) than patients with noninvasive 
infection [66]. 
PCT has been observed to have a high discriminatory value for 
differentiation of erysipelas from deep venous thrombosis with clearly higher 
PCT level (median PCT 0.17 µg/l vs 0.08 µg/l, p=0.001) [67]. In contrast, 
statistically significant differences between these groups in CRP (median 76 
mg/l versus 33 mg/l, p=0.200) or WBC (median 10.7 versus 8.6, p=0.140) 
were not detected [67]. 
In one study PCT, WBC, CRP and erythrocyte sedimentation rate showed 
a positive correlation with the length of hospital stay in patients with 
cellulitis [68], while another study found no correlation between PCT and 
length of in-hospital treatment in patients with SSSI [65]. According to the 
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studies by Lipsky et al and Karppelin et al, CRP has no prognostic value on 
treatment failure of cSSSI [69] or recurrence of cellulitis [70]. 
2.3.2 RADIOLOGY 
In Denver (U.S.), Jenkins et al. detected frequent use of imaging studies 
among hospitalized patients with SSTI but a low yield (4%) for identification 
of deep infection [71]. Imaging studies were performed in total to 82%, plain 
film radiograph to 61%, ultrasonography to 25%, CT to 15% and MRI to 7% of 
the patients, respectively [71]. Furthermore, in the study by Gundersen et al 
ultrasonography was conducted to 73% of the patients with cellulitis and 
ipsilateral deep venous thrombosis was found only in 1% of the patients [72]. 
In necrotizing fasciitis, the routine use of computed tomography (CT) or 
magnetic resonance imaging (MRI) is not recommended – although they 
may show edema extending along the fascial plane [4,28,73]. If necrotizing 
fasciitis is suspected, one should rather perform a deep diagnostic incision 
instead of extensive imaging to prevent the delay to definitive surgical 
treatment [74]. In diabetic foot infection MRI is superior to other imaging 
modalities in diagnosis of osteomyelitis [75] and it is also frequently used in 
the evaluation of need for any kind of surgical intervention [76]. 
 
 
2.4 AETIOLOGY OF CSSSI 
Streptococci and S. aureus are the most common causative agents of non-
purulent and purulent SSSIs, respectively [5,6]. In complicated cases also 
Gram-negative rods and anaerobic bacteria may play a role, as the definition 
of cSSSI suggests [7,8]. The microbiological aetiologies of the various 
infection entities under the umbrella of cSSSI are to be reviewed below in 
detail. 
Bacterial culture is the primary method for detecting the microbiological 
aetiology of SSSI. The sensitivity of bacterial culture is generally higher in 
purulent infections, but in cellulitis only 10–40% of needle aspirations 
[63,77-79] and 20%–30% of punch biopsy specimens [63,80] of the inflamed 
skin were positive. Blood cultures are generally positive in ≤5% of patients 
with cellulitis [81], and in observational studies of cSSSI 4%–6.3% of the 
patients have been reported to be blood culture positive [44,71]. Bacterial 
cultures – especially those of superficial swabs – may detect also bacterial 
colonization in addition to causative microbiological agents and therefore 
tissue specimens from the deeper tissues are preferred to prevent 
unnecessary broad-spectrum antimicrobial treatment [4]. Cultures of blood 





uncomplicated SSSI [4]. However, in patients with severe infection or in 
patients with risk factors for Gram-negative infection, such as malignancy on 
chemotherapy, neutropenia, severe cell-mediated immunodeficiency, 
immersion injuries, and animal bites cultures of blood are recommended and 
cultures and microscopic examination of cutaneous aspirates, biopsies, or 
swabs should be considered [4]. 
2.4.1 CELLULITIS 
β-haemolytic streptococci (BHS), particularly group A and G streptococci, are 
the most common microbiological aetiologies in non-purulent cellulitis 
[5,6,63,82]. Though S. aureus is frequently isolated from skin breaks 
associated to non-purulent cellulitis, it may represent merely a colonization 
and it´s role as a causative agent of non-purulent cellulitis is controversial 
[6,83]. On the contrary, the role of S. aureus has been demonstrated in 
cellulitis associated with an abscess, wound infection or previous penetrating 
trauma [4,84]. Numerous other organisms can also cause cellulitis in special 
circumstances, typically in patients with freshwater (Aeromonas spp.) or 
saltwater (Vibrio ssp.) injuries, neutropenia (Enterobacteria, Pseudomonas 
aeruginosa, Acinetobacter spp.) or severe cell-mediated immunodeficiency 
(Fungi) [4,19,85-87]. 
2.4.2 ABSCESS 
Microbiological aetiology of skin and subcutaneous abscesses can be 
polymicrobial and differ according to the microbiological flora of the skin or 
mucous membranes on the originating site of infection [4,88,89]. Therefore 
a variety of micro-organisms can be isolated from abscesses, including Gram-
positive cocci, Gram-negative bacteria, anaerobes and Clostridium species 
although S. aureus alone is detected in a large percentage of these infections 
[88,90]. In addition to skin flora, IDUs can have an infection caused by 
microbes of oral or faecal flora or environmental contamination [28,89]. 
2.4.3 BITES 
Microbes isolated from infected bite wounds are most often reflective of the 
oral flora of the biting animal or human but may also originate from the 
victim's own skin or the physical environment at the time of injury [4,91]. 
Bite wound infections with purulence are usually polymicrobial. Pasteurella 
species are the most commonly isolated bacteria in infections after dog or cat 
bite and streptococci and staphylococci are the next common isolates [92]. 
Anaerobes are common but rarely the only bacteria found in infected cat or 
dog bite [92]. Capnocytophaga canimorsus infection after a dog bite 
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warrants a special mention due to high risk of systemic complications in 
immunocompromised (particularly in splenectomised) patients [91]. 
Microbiology of infection after human bite is usually complex, frequently 
detected organisms include streptococci, S. aureus, Eikenella corrodens and 
anaerobes, such as Fusobacterium, Prevotella and Peptostreptococcus 
species [93]. 
2.4.4 BURN WOUND INFECTION 
The majority of burn wound infections are polymicrobial with Gram-positive 
bacteria dominance initially but Gram-negative bacteria usually colonize 
burn wounds within a week after injury [28]. In a recent Swedish study 
among patients treated in burn center, the most frequently detected 
microbes were coagulase-negative staphylococci (20%), S. aureus (19%), 
Enterobacteria (16%), enterococci (10%), streptococci (10%), P. aeruginosa 
(4.6%), and Candida spp. (3.9%) [94]. Burn wound infections are frequently 
caused by non-fermenting Gram-negative rods with a high potential to 
antimicrobial resistance. In a South African study, Acinetobacter baumannii 
and P. aeruginosa were the most common microbes isolated in patients with 
severe burns [95]. 
2.4.5 PRESSURE ULCER INFECTION 
Pressure ulcer infections are usually polymicrobial and anaerobic bacteria 
may also play a role, as severely infected pressure ulcers are usually 
associated with a tissue necrosis of some degree [28]. Staphylococcus 
aureus, Proteus mirabilis, P. aeruginosa, and Enterococcus faecalis were the 
most frequently isolated organisms in a recent meta-analysis of the 
microbiology of pressure (decubitus) ulcers among patients with spinal cord 
injury [96]. Similarly, in a very recent Italian study on patients with spinal 
cord injury, S. aureus (31%), P. mirabilis (27%) and P. aeruginosa (16%) 
were the most common bacterial isolates [97]. In addition, they found only 
22% concordance between cultures of superficial swabs and intra-operative 
specimens [97]. 
2.4.6 DIABETIC FOOT INFECTION 
Although usually not detected alone, S. aureus is the major and most 
frequently isolated pathogen in diabetic foot infection (DFI) [8,98,99]. The 
vast majority of moderate-to-severe DFIs are polymicrobial [8,98,99]. 
Detection of Gram-negative bacteria is associated in particular to chronic 
ulcers and prior antibiotic use, detection of P. aeruginosa to some form of 





[98,100]. Enterococci are frequently isolated in DFI, but they often represent 
colonizers rather than true pathogens [98]. Similarly, bacteria commonly 
considered as contaminants, such as coagulase-negative staphylococci and 
corynebacteria, may occasionally be true pathogens in DFI [76]. 
2.4.7 SURGICAL SITE INFECTION 
The rarely occurring very early (<48 hours after operation) emerging surgical 
site infections (SSI) are almost always caused by Streptococcus pyogenes or 
Clostridium spp [4]. SSIs after a clean surgical procedure in areas not 
involving axilla or perineum are most commonly caused by S. aureus or 
streptococcal species, whereas the risk for infection due to Gram-negative 
organism is significant in SSIs after surgery of axilla or perineal region 
[4,101]. In the latter occasion anaerobic bacteria are also frequently detected 
[4,101]. SSIs following operation of intestinal tract or female genitalia have a 
high probability of mixed infection with Gram-positive, Gram-negative and 
anaerobic bacteria [4,102,103]. 
2.4.8 NECROTIZING INFECTIONS 
Necrotizing SSSIs are caused basically by the same microbes as non-
necrotizing SSSIs, but particularly streptococcal and clostridial species are 
isolated more frequently in necrotizing as compared to non-necrotizing 
infections [7,104]. The majority of necrotizing SSSIs are polymicrobial, on 
the average 4.4 microbes per infection were detected by Elliot et al [7] and 
54% of infections were polymicrobial in an Indonesian study [105]. In the 
latter study GAS (24%) was the most common aetiology among 
monomicrobial infections which commonly arise after minor nonpenetrating 
trauma or without a recognized precipitating factor [4,64,105]. Polymicrobial 
infections are most commonly associated with anogenital infection site 
(Fournier´s gangrene), penetrating abdominal trauma, surgical procedures 
involving the bowel, pressure ulcers and injection site infection in IDUs [4]. 
Highly virulent pathogens, such as GAS, S. aureus, Clostridium spp, 
Pasteurella spp (animal bites), Vibrio spp (salt water exposure) and 
Aeromonas hydrophila (freshwater exposure), have a capacity to cause 
fulminant monomicrobial infection also in an immunocompetent host [106-
108]. 
2.4.9 MICROBIOLOGICAL FINDINGS IN OBSERVATIONAL STUDIES 
AND CLINICAL TRIALS OF CSSSI 
The microbiology of cSSSI have been evaluated in several observational 
studies (Table 3) and clinical trials (Table 4). These studies are not directly 
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comparable due to different inclusion and exclusion criteria and differences 
in the presentation of microbiological data. Yet, some general remarks of the 
microbiology of cSSSI can be made. First, microbiological diagnosis is 
obtained for less than half of the patients in observational studies, in 
comparison to two thirds of that in clinical trials. Second, Gram-positive 
pathogens are detected more often than Gram-negative or anaerobic 
bacteria; Gram-positive, Gram-negative and anaerobic bacteria constituted 
altogether 61%–97%, 13%–45% and 2.6%–58% of the microbiological 
diagnoses in the studies, respectively (Tables 3 and 4). Third, in the majority 
of infections a single microbe was detected whereas polymicrobial infections 
were found in 15%–49% of the patients (Tables 3 and 4). Fourth, when 
reported, mixed polymicrobial infections including both Gram-positive and 
Gram-negative microbes constituted usually less than half of the 
polymicrobial infections. Fifth, S. aureus is the most commonly isolated 
pathogen, found in 37%–81% of the cases, of which 5.0%–76% were resistant 
to methicillin (MRSA). 
The percentage of methicillin resistance among staphylococcal SSSIs has 
increased during the last decades particularly due to the increase of 
community-acquired MRSA (CA-MRSA) infections [10,12]. CA-MRSA strains 
are genetically and phenotypically different from health-care associated 
MRSA (HA-MRSA) strains, therefore, some significant differences exists 
between CA-MRSA and HA-MRSA. First, CA-MRSA infections occur 
typically in young otherwise healthy patients without a prior contact to 
health-care whereas HA-MRSA infections affect patients with recent 
hospitalization or other contact to health-care facilities [109]. Second, CA-
MRSA strains often produce Panton-Valentine leucocidin, a toxin that 
destroys white blood cells and is a potent virulence factor [110]. Third, CA-
MRSA strains are typically more susceptible to anti-staphylococcal 
antibiotics than HA-MRSA strains, some strains of CA-MRSA are resistant 
only to β-lactams [111]. 
In a multi-center study, it was found that MRSA was present in one-third 
of cSSSI infections [112]. They detected younger age groups to be more likely 
infected with MRSA as compared to the older ones [112]. Furthermore, 
number of comorbidities and traditional risk factors for healthcare-
associated infection were lower among patients with MRSA infection in 
comparison to patients with non-MRSA infection [112]. 
Globally, the reported resistance rates of S. aureus to methicillin vary 
considerably; based on national registration data the rates were 51% in the 
U.S. and between 0.3% (Norway) and 55% (Portugal) in Europe 2011 [113]. 
The prevalence of MRSA has stayed low in the Nordic countries, 2.8% and 
0.8% of S. aureus isolates were resistant to methicillin in Finland and 






Table 3 Microbiological findings of observational studies on complicated skin and skin 
 structure infection (includes only studies with comprehensive microbiological 









Data collection, years 2010-11 2007 2008-13 2008-09 2005-08 2006-07 
Geographical region Europe US China US US US 
No of patients / 
hospitalizations 
1995 322 575 1033 1096 717 
No of patients with 
microbiological dg 
1001 150 184 525 449 717 
Gram-positive bacteria 70 74 [d] 61 68 [d] 84 [d] 75 
Staphylococci 49 65 46 65 66 53 
    MSSA 28 19 31 31 16 18 
    MRSA 10 43 8 35 50 35 
Streptococci 14 40 12  26 6 
Enterococci 11 3 8  3 15 
Gram-negative bacteria 46 13 49 13 [e] 10 [e] 33 
    Enterobacteriacae 34  34  13 22 
    Pseudomonas   11  4 9 
    Other Gram-negative 12  5  3 3 
Anaerobic bacteria 3 19    3 
Other microorganism 8 3   2 6 
Polymicrobial infections 30  18  15 32 
    Mixed    19 4 10 
Numbers are percentages (%) of the patients with microbiological diagnosis. 
[a] Superficial swabs excluded 
[b] Only cultures obtained <24 h from hospitalisation were included 
[c] Only patients with positive culture <24 h from hospitalisation were included, 52% of the patient 
bacteraemic on admission, 74% of the patient had HAI 
[d] Patients with only Gram-positive bacteria 
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Table 4 Microbiological findings of selected clinical trials for antimicrobial treatment in 
 complicated skin and skin structure infection (includes only studies with 




Noel Corey Gyssens Matthews 
Data collection, years 1998-99 2001-04 2005-06 2007 2006-08 2006-08 
Geographical region America Global Global Global Global Global 
No of patients / 
hospitalizations 
359  828 1378  531 
No of patients with 
microb. dg 
306 540 590 914 511 301 
Gram-positive bacteria 97 85 75 79 [c] 65  
Staphylococci 46 59 66 81 37 58 
   MSSA 44 47 42 51 33 29 
   MRSA 2 12 21 30 4 29 
Streptococci 39 19 9 17 14  
Enterococci 6 7  5 12  
Gram-negative bacteria 45  28 6 [d] 28 42 
   Enterobacteriacae 34 11 [a] 21 12 25  
   Pseudomonas 5  7 4   
   Other Gram-negative 6    1  
Anaerobic bacteria 58 2 [b]   7 5 
Polymicrobial infections 40   30 49 43 
   Mixed    15  19 
Numbers are percentages (%) of the patients with microbiological diagnosis. 
[a] Only number of E. coli infections reported 
[b] Only number of B. fragilis infections reported 
[c] Only Gram-positive bacteria detected 




2.5 ANTIMICROBIAL TREATMENT OF CSSSI 
The effective management of cSSSIs frequently involves a combination of 
antimicrobial therapy and surgical source control [32]. The choice of 
empirical antimicrobial treatment depends mainly on the clinical 
presentation (see aetiology, page 18) and on the antimicrobial susceptibility 
of the potential pathogens – particularly the local prevalence of methicillin-
resistance among S. aureus strains. Exchange of the initial empirical 
treatment to targeted antimicrobial therapy is generally advisable once the 
microbiological aetiology has been determined. Management of infection 
should be initiated as soon as possible. Failure to initiate an antibiotic with 
activity against causative bacteria was the only independent predictor of 
treatment failure in a study of patients with SSSI due to MRSA [124]. 
Prospective randomised studies evaluating the optimal duration of 
antimicrobial treatment in cSSSI have not been made. In a prospective 
randomised study of 121 patients with uncomplicated cellulitis no difference 





levofloxacin – if patient was responding to treatment at day 5 [125]. On the 
other hand, viable streptococci were detected in the tissue specimens of 
patients with necrotizing fasciitis up to 20 days after the initiation of effective 
antimicrobial treatment [126]. An overview of the clinical trials, retrospective 
studies and guidelines evaluating the antimicrobial treatment of cSSSI is 
presented below. 
2.5.1 EVALUATION OF TREATMENT RESPONSE 
Currently, almost all new antimicrobials against Gram-positive bacteria are 
studied before licencing in patients with ABSSSIs. Previously, clinical trials 
on antibiotics covering also Gram-negative and anaerobic bacteria have been 
made under the umbrella of cSSSI (table 5). Traditionally, treatment 
response in clinical trials of cSSSI have been evaluated – typically 7 to 14 
days – after the completion of antimicrobial therapy. Clinical cure was 
usually defined as resolution or near-resolution of signs/symptoms at post-
treatment evaluation (PTE) such that no further antimicrobial therapy was 
required. However, two historical trials [127,128] comparing antibiotic and 
ultraviolet therapy found the difference between treatment arms to be most 
prominent 2–3 days after start of treatment – suggesting that early response 
is a more treatment-specific measure than PTE [129]. Therefore, in 2013 
FDA recommended in their guidance for the development of antimicrobials 
used in ABSSSI the treatment response to be evaluated at 48 to 72 hours 
after initiation of the therapeutic agent instead of traditional post-treatment 
evaluation [24]. The new primary endpoint has also been criticized, mainly 
because early response is not the ultimate goal of antibiotic therapy [130]. 
European guideline still recommends PTE as the primary endpoint [131]. The 
recommended primary endpoint by FDA is ≥20% reduction in infection 
lesion area from baseline [24]. Clinical trials of ABSSSI exploiting the new 
primary endpoint are presented in table 6. 
When the lesion size is evaluated it mainly measures the size of the visible 
inflammatory area instead of measuring the whole infection area. Thus, 
reduction in lesion size may not correspond to reduced bacterial burden or to 
need for antibiotic therapy. This may further complicate the use of 
measurement of the lesion size as the surrogate for treatment response. In 
addition, local and also systemic symptoms of infection may worsen after 
initiation of therapy probably due to sudden destruction of bacteria and 
consequent release of potent cytokines that enhance local inflammation [4]. 
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2.5.2 CLINICAL TRIALS ON ANTIMICROBIAL TREATMENT IN 
PATIENTS WITH CSSSI 
Phase three clinical trials on patients with cSSSI and ABSSSI are presented 
in tables 5 and 6, respectively. Except for one study that included only 
patients with MRSA infection, studies on cSSSI have compared antimicrobial 
therapies covering both Gram-positive and Gram-negative bacteria – or at 
least addition of an antibiotic with Gram-negative coverage was allowed 
beside the study drug that covered only Gram-positive bacteria (Table 5). In 
contrast, studies on ABSSSI have mainly compared antimicrobial agents with 
effect only to Gram-positive bacteria (Table 6). In studies on patients with 
cSSSI, clinical response rates at PTE have varied between 68%–98% (Table 
5). In studies on patient with ABSSSI, clinical response rates at PTE were 
similar (81%–97%) to those of cSSSI and similar or higher than early 48–72 
hours response rates (Table 5 and 6). 
In a clinical trial linezolid was found to be superior to vancomycin in PTE 
of the clinically evaluable population, but patients with linezolid were treated 
statistically significantly longer than patients with vancomycin [132]. 
Friedland et al. conducted a retrospective analysis of two phase 3 clinical 
trials in cSSSI using an early response to treatment as primary endpoint 
[133]. They found ceftaroline to have numerically higher early clinical 
response rates than vancomycin–aztreonam, the difference was not detected 
in the primary analyses using PTE as endpoint [121,133]. Otherwise, the 
efficacy of all the new antimicrobials studied in clinical trials on cSSSI and 
ABSSSI (tables 5 and 6) met the margins for non-inferiority, i.e. were 
equivalent to the comparator drug. This also applies to the single-dose 
treatment with oritavancin, a novel semisynthetic glycopeptide antibiotic. 
The reported mean/median durations of antimicrobial treatment in clinical 
trials of cSSSI and ABSSSI have varied between 6.5 to 14.5 and 6 to 10 days, 
respectively (tables 5 and 6). 
In sub-analyses of clinical trials on patients with cSSSI, lower clinical 
success rates at PTE have been detected in patients with diabetes [134,135] or 
PVD [136] in comparison to patients without these characteristics. Vascular 
insufficiency have shown to decrease antibiotic concentration in peripheral 
tissues which, together with the impaired neutrophil function in diabetics, 













Table 5 Clinical trials (phase 3) on patients with complicated skin and skin structure 














77.5% vs 77.6% 
(95% CI: -8.7, 8.6) 






98.0% vs 93.2% 
(95% CI: -1.7, 
11.3) 
mean 10.0 vs 9.6 







88.6% vs 89.6% 
(p=0.758) 






92.2% vs 92.1% 
(95% CI: -4.4, 4.5) 






91.1% vs 93.3% 
(95% CI: -6.6, 2.1) 






84% vs 80% 
(95% CI: -3, 11.5) 







80.6% vs 84.5% 
(95% CI: -9.4, 2.2) 
mean (SD) 13.5 (4.8) 
vs 14.1 (4.8), iv 6.2 






88% vs 87% 
(95% CI: -2.1, 4.6) 
median 10 vs 11 (study 







90.5% vs 90.2% 
(95% CI: -4.2, 4.9) 






88.9% vs 91.2% 
(p = NS) 







79% vs 82% 
(95% CI: -12.0, 
3.3) 






86.2% vs 82.9% 
(95% CI: -2.8, 9.3) 
mean(SD) iv 5.8(3.2) vs 
6.0(3.4), switch to po 
48% vs 51%, for those 






86.5% vs 88.6% 







94.4% vs 90.4% 
(p = 0.023) 
mean (SD) 11.8 (4.9) 








84.1% vs 80.3% 
(95% CI: -13.3, 
5.8) 
mean (SD) 10.1 (4.7) 






82.4% vs 84.4% 
(95% CI: -10.2, 
6.2) 
mean (SD) 9.1 (3.1) vs 




oxacillin (+dicloxacillin po) 
15-21 
88.6% vs 85.8% 
(CI: −2.5, 8.2) 
mean (SD) 14.3 (4.6) 




cefazolin, oxacillin or 
vancomycin 
14-28 
68.2% vs 70.7% 
(95% CI: −10.1, 
5.1) 
mean (SD) 7.0 (3.2) vs 
8.4 (3.4) in US 
(p<0.001), 7.7 (3.5) vs 
8.7 (3.3), global study 
(p = 0.005) 
[a] Post treatment evaluation, days after the end of treatment 
[b] In clinically evaluable population 
[c] Only patients with MRSA infection included 
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Table 6 Clinical trials (phase 3) on patients with acute bacterial skin and skin structure 
 infection [133,150-154]. 
























vs 74.7% vs 







mean 7.6 vs 
















CI: -2.6, 7.0) 
“high” 
single-dose 










status 92% vs 









success at PTE, 
2.3% early 
responders, but 
failures at PTE 











vs 79.8% (95% 
















vs 79.4% (95% 








success at PTE, 
2% early 
responders, but 
failures at PTE 












vs 66.2% (95% 







 median 7 vs 7 
PTE, post-therapy evaluation 
[a] n = intension-to-treat population 
[b] Retrospective analysis of two clinical trials in patient with cSSSI 
 
2.5.3 OBSERVATIONAL STUDIES ON PATIENTS WITH CSSSI 
In retrospective studies the initial (empiric) antimicrobial treatment was 
clearly divided according to MRSA coverage (table 7). β-lactam antibiotics 
were the most frequently used antimicrobials in areas with low prevalence of 
MRSA, whereas vancomycin dominated in areas with high prevalence of 
MRSA (table 7). In a multinational European survey Garau et al. found a 
wide variation in the selection of antimicrobial therapy as during treatment 
54 different antibiotic agents were used as monotherapy or in combinations 
[44]. The reported mean/median total durations of antimicrobial treatment 





Table 7 The most frequently used initial antibiotics and mean/median total durations of 
 antimicrobial therapy in observational studies on patients with complicated skin 




The most frequently used 











penicillin+β-lactamase inhibitor (29%) 





















3rd generation cephalosporins (22%) 
2nd generation cephalosporins (14%) 









penicillin+β-lactamase inhibitor (37%) 
cephalosporins (18%) 































MRSA, methicillin resistant Staphylococcus aureus 
[a] Carbapenems or piperacillin-tazobactam 
[b] Study included only patients with cellulitis, 31% of infections were complicated 
2.5.4 TREATMENT GUIDELINES FOR SSSI 
Overview of the Finnish and Swedish national guidelines for the treatment of 
mild-to-moderate SSSIs are presented in table 8 which includes also two 
guidelines with an international importance [4,76,156-159]. In the empirical 
treatment of erysipelas and cellulitis guidelines consistently suggest 
treatment targeted to Gram-positive bacteria, except for severe cases (IDSA) 
[4]. In purulent infections (e.g. abscess) coverage of S. aureus is 
recommended and in the areas of high MRSA prevalence (IDSA) an 
empirical antibiotic active against MRSA is suggested [4]. For treatment of 
DFI, Finnish and IDSA guidelines identically suggest antimicrobial treatment 
targeted only to Gram-positives in mild infection and broad-spectrum 
therapy in moderate-to-severe infections (Table 8). The greatest variation 
between guidelines can be found in the recommended duration of 
antimicrobial therapy. For erysipelas and cellulitis, total treatment durations 
of 14–21, 10–14 and 5 (if improving) days are suggested by Finnish, Swedish 
and IDSA guidelines, respectively (Table 8). Based on empirical data, for 
treatment of DFI the IDSA guideline suggests duration of antimicrobial 
therapy between 2 days to ≥3 months based on disease severity, presence of 
osteomyelitis and nature of retained infected tissue after surgical 
intervention [76]. 
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Table 8 Recommended empirical antimicrobial agents and durations of antimicrobial 
 treatment in selected treatment guidelines for skin and soft tissue infections  
 [4,76,156-159]. 







Moderate: penicillin G or 
ceftriaxone or cefazolin or 
clindamycin 
 
Severe: vancomycin + 
piperacillin-tazobactam 
 















Severe: vancomycin or 
daptomycin or linezolid or 
telavancin or ceftaroline 
Antimicrobial therapy 







  Vancomycin or linezolid 
AND piperacillin-tazobactam 
or carbapenem or 










  Clean operation, trunk, 
head, neck, extremity: 
antimicrobial therapy against 
staphylococci 
 
Operation on the axilla, 
perineum, gastrointestinal or 
female genital tract: 
antimicrobial therapy against 
Gram-positives, Gram-
































[a] Bacterial skin infections. Current Care Guidelines. Duodecim 2010. Diabetic foot infections. Current 
Care Guidelines. Duodecim 2009. 
[b] Farmakologisk behandling av bakteriella hud- och mjukdelsinfektioner. Läkemedelsverket och 
Strama. 2009. 
[c] Infectious Diseases Society of America Clinical Practice Guidelines. Skin and soft tissue infections 
2014, diabetic foot infections 2012. 
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[e] Incision & Drainage is the primary treatment, adjunctive antimicrobials recommended only for 
moderate-to-severe cases. 
[f] Antimicrobial therapy in adjunction to early aggressive surgical source control recommended. 
[g] Opening of the surgical incision, adjunctive antimicrobials if systemic signs of infection (IDSA and 
WSES), erythema > 5 cm from incision or any necrosis (IDSA), source control incomplete (WSES) or 
immunocompromised patient (WSES). 






2.6 SURGICAL TREATMENT OF CSSSI 
Need for surgical treatment was included as one of the criteria of cSSSI in the 
FDA guidance document for the development of new antimicrobials [17]. 
Early and aggressive surgical treatment – debridement or drainage – is the 
cornerstone in the management of cutaneous abscess, surgical site infection, 
diabetic foot infection and especially necrotizing infections [4,76,159]. In 
retrospective studies on patients with cSSSI, totally 36%–44% of patients 
had significant surgical intervention(s) after the diagnosis of cSSSI 
[44,45,47,160]. 
2.6.1 CUTANEOUS ABSCESS 
Incision and evacuation of pus and debris is the primary treatment of 
cutaneous abscesses [4]. Incision and drainage of skin abscesses were 
compared to ultrasonographically guided needle aspiration in a randomized 
trial [161]. At day 7 the overall success rates of incision and drainage 
compared to ultrasonographically guided needle aspiration were 80% and 
26%, respectively, indicating that the latter is insufficient therapy for skin 
abscesses [161]. The addition of systemic antibiotics to incision and drainage 
has usually not improved cure rates in randomized studies [162-164], but a 
preventive effect on recurrence of other abscesses have been detected 
[162,164]. In two recent U.S. study among patients with drained cutaneous 
abscess, however, adjunctive trimethoprim-sulfamethoxazole (93%) and 
clindamycin treatment (93%) resulted in a statistically significantly higher 
cure rate than placebo (81–86%) in per-protocol population [165,166]. IDSA 
guideline suggests systemic antibiotics to be given for patients with severely 
impaired host defenses or signs or symptoms of systemic infection [4]. 
2.6.2 SURGICAL SITE INFECTION (SSI) 
Based on empirical data, for SSIs guidelines (IDSA and WSES) suggest to 
open the incision, evacuate the infected material, and continue dressing 
changes until the wound heals by secondary intention [4,28]. In the single 
prospective randomized trial on patients with SSI statistically significant 
effect of adjunctive antibiotic treatment was not detected [167]. However, 
adjunctive systemic antimicrobial therapy is recommended if systemic signs 
of infection are present (IDSA and WSES), or erythema reaches >5 cm from 
incision margins (IDSA), or any wound necrosis (IDSA), or source control is 
incomplete (WSES) or patient is immunocompromised (WSES) [4,28]. 
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2.6.3 DIABETIC FOOT INFECTION 
In addition to antimicrobial therapy, surgical interventions are frequently 
needed in patients with moderate-to-severe DFI, and in life- or limb-
threatening infections or if the affected limb is ischemic the need for those is 
mostly urgent [76]. These surgical procedures can be minor, such as drainage 
of abscess or debridement of devitalized tissue, or major, such as 
amputation. In an American survey among diabetics, cSSSI accounted for 
59% of lower limb amputations [168]. Bone resection has been regarded as 
integral part of treatment in DFI with chronic osteomyelitis [169] but this 
view has been challenged by the reports from retrospective studies that have 
demonstrated success rates of 65%–80% with prolonged (3–6 months) 
antibiotic treatment alone [170-174]. Vascular surgeon should be consulted if 
ischemia of the infected limb is suspected [175]. 
2.6.4 NECROTIZING INFECTIONS 
Early recognition and urgent surgical debridement were the most critical 
factors for reducing mortality in retrospective analysis of patients with 
necrotizing infections [176]. Repeated daily debridement is recommended 
until the surgical team finds no further need for debridement [4,28]. In the 
empirical antimicrobial treatment of necrotizing fasciitis a broad-spectrum 
antimicrobial treatment is recommended in guidelines [4,28]. In the 
treatment of GAS necrotizing fasciitis an addition of protein synthesis 
inhibitor (high dose clindamycin or linezolid) to cell-wall active antibiotic (β-
lactam) therapy has been associated to better outcome in retrospective 
studies [177,178]. Similar desirable effect of protein synthesis inhibitors to 
exotoxin production of Gram-positive bacteria was detected also in S. aureus 
[179]. However, in a recent prospective randomized study on patients with 
limb cellulitis the addition of a short course of clindamycin to flucloxacillin 
treatment did not improve outcome at day 5 [180]. 
Despite the theoretically desirable effects, the role of intravenous 
immunoglobulin and hyperbaric oxygen therapies in the treatment of 
necrotizing fasciitis is controversial; no high quality evidence is supporting 
their use. In a small randomized study on 21 patients with GAS necrotizing 
fasciitis, a significant decrease was detected among patients with intravenous 
immunoglobulin treatment in the sepsis-related organ failures at day 2–3, 
but not in the primary outcome (mortality at 28 days) [181]. The expert panel 
of WSES supports the use of early intravenous immunoglobulin therapy in 
patients with severe sepsis or septic shock and the use of hyperbaric oxygen 
therapy in those hospitals where the hyperbaric chamber is available – as an 





2.7 OUTCOME AND THE USE OF RESOURCES IN CSSSI 
In real-life observational studies of cSSSI the 30-day mortality rates have 
been 0.4%–9.0% and recurrences have been detected in 3.7%–8.6% of the 
patients [25,43-46,71]. Necrotizing fasciitis has significantly higher mortality 
rate; mean mortality was 21.5% in a recent review with 1463 patients [182]. 
In observational studies higher mortality rate has also been detected among 
patients with nosocomial infection, co-morbidities and age over 65 years as 
compared to patients without these characteristics [44,46,117]. 
In practice, patients with cSSSI who survive eventually have their 
infection cured and chronically persistent symptoms of active infection do 
not exist. Therefore, the frequency of recurrence and length of hospital stay 
and length of antimicrobial treatment may be used as indicators for 
treatment efficacy – and for the use of resources. A great difference in the 
mean/median length of hospital stay between U.S. and Europe have been 
detected in the retrospective studies on patients with cSSSI: 4–5 days in U.S. 
and 11.8–20.6 days in Europe (Table 5). Important to note when estimating 
the costs of infection management, is that the costs of hospitalization 
constitute the majority of total costs – up to 81% in a Canadian study on 
patients with MRSA [183-185]. The total median costs of cSSSI 
hospitalization have varied from 1’643 USD in China to 13’240 USD in U.S. 
[47,71]. Furthermore, in an American study higher median total costs were 
observed among patients with Gram-positive infection (19’894 USD) than 
those with mixed infection (26’935 USD) [186]. In observational studies, 
intensive care unit (ICU) admissions are reported in 4.0–6.5% of cases 
[44,71]. 
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3 AIMS OF THE STUDY 
 
The objectives of this study were: 
 
 
I To assess the treatment reality of patients with a complicated skin and 
 skin structure infection in two low resistance areas in focus of patient, 
 disease and treatment characteristics and outcome. 
 
II To study the feasibility of early treatment response criteria in a 
 population-based real-life setting and to evaluate factors associated 
 with the time to clinical stability and the association of early response 
 with outcome in patients with complicated skin and skin structure 
 infection. 
 
III To evaluate differences in microbiological aetiology and treatment 
 practices between diabetics and nondiabetics in a population-based 
 set-up of complicated skin and skin structure infection.   
 
IV To compare the characteristics and treatment practises of complicated 
 skin and skin structure infection between two areas with low incidence 






4 MATERIALS AND METHODS 
4.1 STUDY DESIGN 
The design was an observational retrospective cohort study. The study 
population consisted of all adult residents from cities with nearly equal 
population (Helsinki, Finland population of 588’000 and the Gothenburg 
area, Sweden population 600’000) who were treated in hospital because of 
cSSSI during 2008–2011. The study hospitals, Helsinki University Central 
Hospital and Helsinki City Hospital in Finland and Sahlgrenska University 
Hospital, Gothenburg area in Sweden, have the only emergency departments 
on their catchment area and are thus responsible for treatment of almost all 
hospitalized SSSI infections. Data for the study was collected from the 
electronic patient medical record databases of these hospitals by IJ in 
Helsinki and by LH and trained nurses in Gothenburg. 
First, medical records of all patients with ICD-10 codes possibly suitable 
for SSSI (table 9) were reviewed and patients who met the inclusion criteria 
for cSSSI (Table 10) were included in the analysis. For the final analysis 
population, data was collected on patient demographics, microbiology, signs 
and courses of the disease. Co-morbidities of interest were diabetes, 
peripheral vascular disease, congestive heart disease and chronic renal, liver 
or respiratory disease, malignancy, human immunodeficiency virus infection 
or any other disease with immune system impairment. In addition, data 
about patient care, antimicrobial and other treatments in various 
departments, treatment response and one-year post-cSSSI diagnosis follow-
up information was collected. 
4.2 STUDY DEFINITIONS 
The classification of cellulitis/fasciitis was harmonized between centers post-
hoc; patient had cellulitis/fasciitis if there was no abscess, diabetic foot/leg 
ulcer or peripheral vascular ulcer. The definition of DFI was based on typical 
clinical presentation with infected (traumatic) wound or (neuropathic) 
ulceration. Due to requirement of systemic sings of infection in the study, the 
DFIs of were classified as severe on IDSA classification [76]. Clinical stability 
was assessed from patient records and it was defined as improvement of 
systemic symptoms such as fever and vital signs (pulse rate, blood pressure) 
along with local signs of infection. Criteria for treatment failure were: need 
for unplanned surgery due to infection, no improvement in clinical situation 
after 5 days of treatment or treatment failure registered in patient records by 
treating physician. 
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Infection was defined as health-care associated (nosocomial) if the patient 
had undergone invasive surgery or had been hospitalized within the previous 
three months. Microbiological diagnosis was obtained by routine bacterial 
cultures of blood, tissue specimens or superficial swabs. Results of deep 
tissue samples were preferred in case of multiple specimens yielding 
potential aetiological agents. In the microbiological analysis of studies II and 
III, candida and coagulase negative staphylococci were not regarded as true 
pathogens. Carbapenems and piperacillin-tazobactam were considered as 
broad-spectrum antimicrobial therapy in the analysis. To enable the 
comparison between the cities, departments Helsinki City hospital was 
combined to the department of Medicine and treatment at Home hospital 
(Helsinki) was regarded as home-based care in the analyses. Since the Home 
hospital had treatment facilities similar to in-patient treatment (e.g. 
intravenous antibiotics) the treatment was included to the total LOS. Home-
based care included follow up of cure, wound care or other forms of nursing. 
The study was approved by both study sites in local conventional manner and 
the ethical committee of Sahlgrenska University Hospital. 
 
 
Table 9 ICD-10 diagnostic codes used in the primary patient selection from hospital 
 databases. 
ICD-10 codes Diagnosis in text 
A46 Erysipelas 
A48.0 Gas gangrene 
L02 Cutaneous abscess, carbuncle and furuncle 
L03 Cellulitis 
L04 Acute lymphadenitis 
L05.0 Pilonidal cyst with abscess 
L08 Other local infections of skin and subcutaneous tissue 
L97 Ulcer of lower limb, not elsewhere classified 
M72.6 Necrotizing fasciitis  
O86.0 Infection of obstetric surgical wound 
T79.3 Posttraumatic wound infection, not elsewhere classified 
T81.4 Postoperative infection 
T82.7 Infection due to other vascular device, implant and graft 








Table 10 Inclusion and exclusion criteria for the final analysis population, i.e. criteria of 
 complicated skin and skin structure infection in the study. 
Inclusion criteria 
The patient’s age was ≥18 years at the time of hospitalization 
The patient was hospitalized 
The patient required treatment with antimicrobials 
The infected lesion fitted at least one of the following descriptions: 
• It affected deeper soft tissue (e.g. cellulitis, fasciitis, etc) 
• It required significant surgical intervention (such as wound infection – surgical or traumatic)  
• It developed on a lower extremity in a subject with diabetes mellitus or well-documented 
peripheral vascular disease 
• It was a major abscess, infected ulcer or deep and extensive cellulitis. 
The patient had at least two local signs of cSSSI (purulent or seropurulent drainage/discharge, 
erythema, fluctuance, heat/localized warmth, pain/tenderness to palpation, swelling/induration) plus 
at least one systemic sign (temperature of >38 or <36°C, white blood cell count of >10,000/mm3 or 
<4,000/mm³, or >10% immature neutrophils). 
Exclusion criteria 
The patient was participating in other clinical trial or interventional study 
The patient had an uncomplicated SSSI such as simple abscesses, impetiginous lesions, superficial 
cellulitis, furunculosis, carbunculosis, or folliculitis. Or the patient had skin and skin-structure 
infections with a high cure rate after surgical incision alone or after aggressive local skin care (e.g., 
surgical wound infection with less than 5 cm of erythema surrounding the wound margin). 
Definitions 
Wound infection: purulent / seropurulent discharge or >5 cm of erythema (i.e. cellulitis) surrounding 
the wound margin. 
Abscess: loculated fluid collection with >2 cm of erythema (i.e. cellulitis) extending from the abscess 
margin. A “major abscess” either extended to deeper soft tissue or required significant surgical 
intervention. 
Cellulitis: advancing erythema, oedema and heat. “Deep and extensive cellulitis” involved deeper soft 
tissue and had a surface area > 10 cm². 
Significant surgical intervention: a major operative procedure, not including commonly performed 
minor procedures such as incision and drainage of abscesses performed at the bedside, suture 
removal, needle aspiration, superficial debridement of devitalized tissue, or routine wound care. 
Deeper soft tissue: a subdermal tissue, including subcutaneous fat; for example, extension of 
infection to muscle or fascia constitutes evidence of deeper soft tissue involvement. 
 
4.3 STATISTICAL METHODS 
Categorical variables were summarized using counts and percentages and 
continuous variables using means, standard deviation, median, first and 
third quartile, min and max values. 
 
Study I. Due to low frequency of a number of variables in some subgroups, 
p-values for differences between subpopulations have been calculated using 
Fisher’s exact test. A two sample t-test was used to test for difference 
between two subgroups while for difference between three or more 
subgroups the analysis of variance (ANOVA) with subgroup as a fixed factor 
was utilized. If assumption of normal distribution was violated Wilcoxon 
rank-sum test was used. 
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Study II. The main outcome measure was time to clinical stability. Patients 
were divided into two groups according to time from diagnosis of cSSSI to 
clinical stability – within 0–3 days or >3 days – in line with the FDA 
recommendation [24]. In addition, a subgroup of 4–5 days to clinical 
stability was defined to test whether this subgroup of patients shared 
similarities with the patients of 0–3 days or ≥6 days groups. Patients who 
died before they reached clinical stability or those with day of clinical 
stability unknown were excluded from the analyses. 
On univariable analysis categorical variables were compared with the 
Pearson’s Χ2- or the Likelihood ratio –test and for continuous variables the 
Mann-Whitney U -test was utilized. Odds ratios (OR) with 95% confidence 
intervals (CI) were calculated. Multivariable logistic regression analysis with 
backward selection was performed including 1) all clinically relevant 
variables and 2) those having univariable p-values less than 0.15 and 3) were 
not multicollinear [187]. The model with lowest Akaike information criteria 
(AIC) was the final multivariable model [188]. All tests were two-tailed and 
p-value <0.05 was considered as significant. SPSS version 21.0 (SPSS Inc., 
Chicago, IL, USA) were used for analyses. 
 
Study III. Patients were divided into three separate groups: diabetics, non-
diabetics and patients with diabetic foot infection (DFI). Pearson´s Χ2 test 
and Mann-Whitney U -test were applied in the analyses of categorical 
variables and non-parametric data, respectively. Odds ratios (OR) with 95% 
confidence intervals (CI) were calculated and univariate factors with p-value 
≤0.1 were included into binary logistic regression multivariate analysis. 
To verify the stability of the main results, a Propensity-score (PS) was 
calculated by logistic regression for the assignment of either i) broad-
spectrum or non-broad-spectrum or ii) short (<17 days) or long (≥17 days) 
definitive antimicrobial treatment. Variables interpreted as relevant for this 
assignment were age >60, chronic renal failure, respiratory disease and 
injection drug abuse. Next, a PS-adjusted binary logistic regression 
multivariate analysis was performed to estimate treatment characteristics 
specific for patients with a diagnosis of diabetes. All tests were two-tailed and 
p-value <0.05 was considered as significant. Analyses were done using SPSS 
version 21.0 (SPSS Inc., Chicago, IL, USA). 
 
Study IV. The Fischer´s exact test and Cochran-Mantel-Haenszel statistics, 
controlling for age, were utilized in the statistical analyses of categorical 
variables. For continuous variables a two sample t-test or the analysis of 
variance (ANOVA) were used to test for difference between two subgroups 
and if assumption of normal distribution was violated, also Wilcoxon rank-






5.1 CHARASTERISTICS OF CSSSI IN TWO NORDIC 
CITIES (STUDY I) 
 
Figure 2 The study flowchart. Footnotes: [a] See table 9. [b] See table 10. [c] Of the 219  
  patients in Helsinki, 191 were identified at Helsinki University Central Hospital and 
  28 at Helsinki City Hospital. 
5.1.1 PATIENT POPULATION 
Totally, 3315 patients were identified by ICD10-codes and 460 patients met 
the inclusion criteria for the final analysis population (Figure 2). Within the 
study period, the average annual incidences of cSSSI were 9/100’000 and 
11/100’000 in Helsinki and Gothenburg, respectively. The patients’ mean age 
was 60.8 years and the majority (61%) of them were male (Study I, Table 1). 
The minority of patients (24%) had no underlying diseases, whereas 38%, 
26% and 12% of patients had 1, 2 and ≥3 co-morbidities, respectively. The 
most common chronic underlying conditions were diabetes (41%), peripheral 
vascular disease (29%), congestive heart disease (9.3%), chronic renal 
disease (8.7%), malignancy (7.8%) and respiratory disease (7.4%) (Study I, 
Table 1). Alcohol and injection drug abuse were detected in 8.7% and 7.0% of 
patients, respectively. Totally 25% of infections were classified as healthcare-
associated, 18% of patients had previous hospitalization and 16% had 
underwent an invasive surgical procedure. Thirty-three persent of patients 
had received antibiotic treatment within the previous three months before 
cSSSI. After the onset of symptoms of infection but before fulfillment of the 
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used diagnostic criteria of cSSSI, antibiotic treatment was given orally to 23% 
and intravenously to 6.1% of patients. 
5.1.2 CLINICAL DIAGNOSIS 
Diagnosis of cSSSI was made in 28% of patients within 2 days, in 50% 
between days 2 to 7 and in 20% later than 7 days after the symptoms 
appeared. Bacteraemia was detected in 13% of patients and the average 
maximal CRP level was 222 (SD 129) mg/L. At the time of diagnosis or later, 
16% of patients were admitted to Intensive Care Unit (ICU), 5.0% met the 
criteria for septic shock and 28% needed blood pressure support (fluid 
resuscitation or vasopressor therapy). The majority of patients had cellulitis 
(42%) or abscess (40%) and infections of post-surgical wound (17%), diabetic 
foot/leg ulcer (15%), peripheral vascular disease ulcer (12%), and post-
traumatic wound (11%) were also frequently detected types of infection 
(Study I, Table 2). 
5.1.3 MICROBIOLOGICAL DIAGNOSIS 
Microbiological tests were taken from 94% and diagnosis was obtained in 
69% of the total patient population. Microbiological diagnosis was based on 
the culture of blood, tissue sample or superficial swab in 17%, 6.3% and 77% 
of the patients, respectively. Monomicrobial infections (50%) were more 
common than polymicrobial infections (24%, Study I, Table 3). 
Staphylococcus aureus and streptococci were the most commonly isolated 
pathogens in monomicrobial infections, identified in 21% and 16% of the 
microbiologically tested patients, respectively (Study I, Table 3). Among 
staphylococcal infections, methicillin sensitive S. aureus (21%) was the most 
common, coagulase-negative staphylococci (3.2%) and methicillin resistant 
S. aureus (0.7%) were detected less often. Streptococcus pyogenes (9.3%) 
and other β-hemolytic streptococci (5.6%) were the most frequently detected 
streptococci. Gram-negative and anaerobic bacteria were less common – and 
if detected – they were found more often in conjunction with other microbe 
(16%) than as a single pathogen (6.0%). β-hemolytic streptococci (51%) and 
S. aureus (31%) constituted the majority of bacteraemic infections. 
5.1.4 ANTIMICROBIAL THERAPY 
Data on antimicrobial treatment was available for 458 patients. Initial 
antimicrobial therapy after diagnosis of cSSSI was intravenous in 92% of 
patients and mainly classified as empirical (89% of patients). Totally 23 
different antibacterial agents were used in initial therapy, among which 





subsequent therapy, 29 different agents in total were used. Again, 
cephalosporins (23%) were the most utilized antibiotics, whereas 
clindamycin was the most common single agent (15%). Antibiotics with 
MRSA-coverage (vancomycin, linezolid or tigecycline) were rarely used in the 
study, for initial therapy in 0.4% and for subsequent therapy in 3.9% of 
patients. 
During treatment with antibiotics, in average 3.5 (SD 2.1) different 
antimicrobial agents were used per patient and the median overall duration 
of antimicrobial therapy was 17 days. The median durations of intravenous 
and oral antimicrobial treatment were 9 days (range 1–372 days) and 14 days 
(range 2–570 days), respectively. In subgroup analysis, factors associated to 
longer total duration of antimicrobial treatment were the presence of co-
morbidities, diabetes, bacteraemia, higher peak CRP level and initial 
antimicrobial treatment with a broad-spectrum antibiotic (Table 11). 
During the period of intravenous therapy, initial treatment was modified 
to another intravenous drug in 39% of cases and in 5% of patients the reason 
for modification was direction of therapy according to microbiological results 
(streamlining). In comparison to patients without these characteristics, 
patients with surgical intervention after diagnosis of cSSSI, bacteraemia, 
admission to ICU and higher peak CRP level had more often their treatment 
streamlined (Table 11). The median time from diagnosis to the first 
modification was 3 days (mean 4.7 days, SD 6.5) (Study I, Figure 1). Only 
5.4% of patients completed their therapy with the same agent that the 
treatment was started with (Study I, Table 2). Oral antimicrobials were 
prescribed for 64% of patients after intravenous treatment. Cephalexin 
(33%), clindamycin (25%), fluoroquinolones (15%) and flucloxacillin (14%) 
were the most common antibiotics used after discharge. 
Surgical intervention after diagnosis of cSSSI was conducted to 52% of the 
patients and 20% had more than one intervention during their disease 
course. Patients with surgical intervention after diagnosis of cSSSI had in 
average longer LOS than patients without surgical intervention (16 versus 11 
days), but statistically significant difference was not found in the total 
duration of antimicrobial treatment (Table 11). 
5.1.5 CLINICAL OUTCOME 
The median time to clinical stability was 3 days (Study I, Figure 1) and 
treatment failure was detected in 38% of patients – in 82% of cases it was 
due to cSSSI. Clinical failure occurred more often in patients with surgical 
intervention after diagnosis of cSSSI, bacteraemia, admission to ICU, higher 
peak CRP-level and initial antimicrobial treatment with a broad-spectrum 
agent when compared to patients without these characteristics. In the total 
analysis population, the median LOS was 13 days, but nearly half (46%) of 
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patients had home-based care after discharge. Bacteraemia, higher peak CRP 
level, admission to ICU and need for surgical intervention after diagnosis of 
cSSSI were the factors associated to longer LOS (Table 11). 
The overall mortality in 30 days was 4% and in 12 months 12%. 
Admission to ICU was the only factor associated to higher mortality in 30 
days (13% versus 2.6%, p=0.0015). Sixteen percent of patients were 
hospitalized again due to SSSI within 12 months after initial discharge and 
the presence of a co-morbidity (20% versus 5.6%, p=0.0003) was the only 
factor associated to the higher risk of recurrence. Patients with a recurrence 
had been treated longer for their primary episode of cSSSI (median total 
durations of antibiotic treatment 25 days) than patients without a 
recurrence; (20 days, p=0.0012, n=294). In the analysis of the association of 
microbiological aetiology to outcome, pathogens were grouped as follows: 
only methicillin sensitive S. aureus, only streptococci, multiple bacteria and 
microbiological diagnosis negative or unknown. In this analysis, 
microbiological aetiology had no statistically significant association to 
clinical outcomes presented in table 11. In subgroup analysis, higher peak 
CRP level was associated with longer LOS and total duration of antimicrobial 
therapy, higher rate of treatment modifications, streamlining, and treatment 
















































Total duration of 
antibiotic 
treatment, days 
(IV + PO only) 
median 
No co-morbidity (n=112) 42 (37.5%) 8 (7.1%) 21 (18.8%) 8 (n=105) 16 (n=81) 
>1 co-morbidities (n=348) 135 (38.8%) 15 (4.3%) 85 (24.4%) 14 (n=313) 22 (n=223) 
p-value 0.8243 0.2226 0.2465 0.1072 0.0326 
Diabetes (n=187) 72 (38.5%) 8 (4.3%) 50 (26.7%) 15 (n=167) 26 (n=118) 
No diabetes (n=273) 105 (38.5%) 15 (5.5%) 56 (20.5%) 11 (n=251) 17 (n=186) 
p-value 1.0000 0.6655 0.1427 0.1977 0.0106 
Nosocomial [a] (n=114) 43 (37.7%) 7 (6.1%) 33 (28.9%) 13 (n=102) 18 (n=78) 
Non-nosocomial [a] (n=346) 134 (38.7%) 16 (4.6%) 73 (21.1%) 13 (n=316) 22 (n=226) 
p-value 0.9118 0.6198 0.0956 0.9762 0.7080 
Surgical intervention (n=240) 100 (41.7%) 18 (7.5%) 86 (35.8%) 16 (n=215) 19.5 (n=156) 
No surgical interv. (n=220) 77 (35.0%) 5 (2.3%) 20 (9.1%) 11 (n=203) 21.5 (n=148) 
p-value 0.1510 0.0103 <.0001 <.0001 0.8799 
Bacteraemia (n=61) 37 (60.7%) 10 (16.4%) 21 (34.4%) 21 (n=52) 29.5 (n=38) 
No bacteraemia (n=399) 140 (35.1%) 13 (3.3%) 85 (21.3%) 12 (n=366) 19 (n=266) 
p-value 0.0002 0.0002 0.0328 0.0012 0.0058 
Admitted to ICU (n=73) 55 (75.3%) 10 (13.7%) 39 (53.4%) 31 (n=55) 33 (n=44) 
Not admitted to ICU (n=387) 122 (31.5%) 13 (3.4%) 67 (17.3%) 11 (n=363) 19 (n=260) 
p-value <.0001 0.0011 <.0001 <.0001 0.1005 
Highest 
CRP 
 <100 (n=81) 8 (9.9%) 1 (1.2%) 4 (4.9%) 6.5 (n=78) 16.5 (n=56) 
 100-200 (n=138) 38 (27.5%) 3 (2.2%) 27 (19.6%) 12 (n=127) 18 (n=87) 
 >200 (n=232) 129 (55.6%) 19 (8.2%) 72 (31.0%) 17 (n=207) 26.5 (n=158) 
p-value <.0001 0.0107 <.0001 0.0002 0.0038 
MSSA only (n=90) 31 (34.4%) 2 (2.2%) 20 (22.2%) 9.5 (n=82) 17 (n=56) 
Streptococci only (n=72) 35 (48.6%) 6 (8.3%) 15 (20.8%) 14 (n=64) 21 (n=45) 
Negative/unknown (n=113) 50 (44.2%) 5 (4.4%) 25 (22.1%) 14 (n=105) 24 (n=86) 
Multiple bacteria (n=92) 38 (41.3%) 9 (9.8%) 31 (33.7%) 13 (n=84) 21 (n=70) 
p-value 0.3031 0.1142 0.1716 0.3429 0.8658 
Broad-spectrum [b] (n=87) 35 (40.2%) 4 (4.6%) 32 (36.8%) 17.5 (n=78) 29 (n=49) 
Cefalosporins [c] (n=224) 99 (44.2%) 13 (5.8%) 56 (25.0%) 14 (n=208) 23 (n=168) 
Other [d] (n=42) 11 (26.2%) 2 (4.8%) 6 (14.3%) 7 (n=34) 12.5 (n=26) 
Penicillins [e] (n=53) 20 (37.7%) 1 (1.9%) 8 (15.1%) 13 (n=50) 21 (n=33) 
Pen. with staph. ef.[f] (n=52) 10 (19.2%) 3 (5.8%) 4 (7.7%) 7.5 (n=46) 16 (n=28) 
p-value 0.0057 0.8704 0.0004 0.003 0.025 
Fishers exact test have been used to calculation of p-values for categorical values. 
T-test have been used for calculation of p-values for difference between two subgroups, 
one-way ANOVA for difference between three or more subgroups for continuous variables. 
CRP, C-reactive protein. MSSA, Methicillin sensitive Staphylococcus aureus. 
[a] Patient had been hospitalized or had undergone invasive surgery within previous 3 months 
[b] Carbapenem and Piperacillin-Tazobactam 
[c] Cefadroxil, Cefotaxim, Ceftazidim, Ceftriaxone, Cefuroxime, Cephalexin and Cefazolin 
[d] Aztreonam, Clindamycin, Colistin, Doxycyklin, Fluoroquinolone, Fusidic Acid, Linezolid, Metronidazol, 
Netilmycin, Rifampicin, Tetracyclin, Tigecyclin, co-trimoxazole, Tobramycin, Unknown and Vancomycin 
[e] Amoxicillin, Ampicillin, Benzylpenicillin and Phenoxymethylpenicillin 
[f] Amoxicillin + Clavulanic Acid, β-lactamasestable Penicillin, Cloxacillin, Dicloxacillin and Flucloxacillin 
[g] Only IV to IV modifications 
[h] Initial treatment modification, reason: Directed antimicrobial treatment according to microbiological results 




5.2 FACTORS ASSOCIATED WITH TIME TO CLINICAL 
STABILITY IN CSSSI (STUDY II) 
 
Totally 402 patients were included in the analysis of clinical stability and 
time to clinical stability varied between 0–50 days. Two hundred thirty-nine 
(59%) patients reached stability in 0–3 days and 163 (41%) after 3 or more 
days (Figure 3, Table 12). 
 
Figure 3 Time to clinical stability from the day of cSSSI diagnosis (n=402). 
5.2.1 CLINICAL STABILITY ON 0–3 VERSUS ≥4 DAYS 
On multivariable analysis (n=308), factors statistically significantly 
associated to clinical stability on ≥4 days were as follows: posttraumatic 
wound infection, bacteraemia, diabetes, a short (<2 days) time from onset of 
symptoms to diagnosis of cSSSI, admission to ICU, a surgical intervention 
after diagnosis of cSSSI and initial treatment with a broad-spectrum 
antimicrobial agent (Table 12). On the contrary, previous hospitalization 
within the three months before infection and initial antimicrobial treatment 
covering initial pathogens were the factors that remained statistically 
significantly associated with stabilization on 0–3 days on multivariable 





Table 12 Baseline and disease characteristics, microbiological diagnosis and 
 antimicrobial treatment of 402 patients with cSSSI categorized according to time 









≥4 vs 0-3 days 
Clinical stability 
≥4 vs 0-3 days 
Multivariable analysis [a] 
Full analysis population (N=402) 239 163 OR (95% CI) p [b] OR (95% CI) p 
Baseline characteristics 
Male gender (n=240) 127 (53) 113 (69) 1.99 (1.31-3.03) 0.001 ---  
Age > 60 years (n=253) 146 (61) 107 (66) 1.22 (0.80-1.84) 0.35 ---  
Injection drug abuse (n=31) 22 (9) 9 (6) 0.58 (0.26-1.29) 0.17   
Alcohol abuse (n=33) 13 (5) 20 (12) 2.43 (1.17-5.04) 0.015 ---  
Congestive heart disease (n=29) 16 (7) 13 (8) 1.21 (0.57-2.58) 0.63   
Respiratory disease (n=31) 15 (6) 16 (10) 1.63 (0.78-3.39) 0.20   
Chronic renal failure (n=26) 13 (5) 13 (8) 1.51 (0.68-3.34) 0.31   
Liver disease (n=21) 10 (4) 11 (7) 1.66 (0.69-4.00) 0.26   
Cancer/Malignancy (n=31) 22 (9) 9 (6) 0.58 (0.26-1.29) 0.17   
Diabetes (n=158) 81 (34) 77 (47) 1.75 (1.16-2.63) 0.007 2.33 (1.28-4.25) 0.006 
Peripheral vascular disease (n=97) 49 (21) 48 (29) 1.62 (1.02-2.57) 0.041 1.82 (0.93-3.58) 0.08 
Hospitalization within 3 months (n=76) 53 (23) 23 (14) 0.58 (0.34-0.99) 0.040 0.47 (0.22-0.99) 0.047 
Inv. surgery within 3 months (n=67) 47 (20) 20 (13) 0.57 (0.32-1.01) 0.047 ---  
Disease characteristics 
Abscess (n=172) 121 (51) 51 (31) 0.44 (0.29-0.67) <0.001 0.55 (0.29-1.04) 0.07 
Cellulitis/fasciitis (n=171) 86 (36) 85 (52) 1.94 (1.29-2.91) 0.001 ---  
Posttraumatic wound (n=42) 19 (8) 23 (14) 1.90 (1.00-3.62) 0.05 3.17 (1.31-7.69) 0.011 
Postsurgical wound (n=76) 46 (19) 30 (18) 0.95 (0.57-1.58) 0.83   
Decubitus/pressure ulcer (n=10) 8 (3) 2 (1) 0.36 (0.08-1.71) 0.16   
Diabetic foot/leg ulcer (n=53) 24 (10) 29 (18) 1.94 (1.08-3.47) 0.026 ---  
Perip. vascular disease ulcer (n=35) 22 (9) 13 (8) 0.86 (0.42-1.75) 0.67   
Antibiotic treatment before dg (n=108) 68 (28) 40 (25) 0.82 (0.52-1.29) 0.38   
Symptoms <2 days before dg (n=117) 56 (24) 61 (38) 1.95 (1.26-3.02) 0.003 2.01 (1.02-3.94) 0.043 
Bacteraemia (n=50) 15 (6) 35 (21) 4.08 (2.15-7.77) <0.001 3.09 (1.36-7.02) 0.007 
Admission to intensive care unit (n=58) 9 (4) 49 (30) 11.0 (5.21-23.2) <0.001 10.1 (4.01-25.3) <0.001 
Surgical intervention after dg (n=211) 114 (48) 97 (60) 1.61 (1.08-2.41) 0.020 2.64 (1.36-5.11) 0.004 
Initial microbiological diagnosis 
Staphylococci (n=99) 70 (29) 29 (18) 0.52 (0.32-0.85) 0.008 ---  
Streptococci (n=90) 48 (20) 42 (26) 1.38 (0.86-2.22) 0.18   
Gram-negative bacteria (n=24) 15 (6) 9 (6) 0.87 (0.37-2.05) 0.75   
Polymicrobial infection (n=79) 40 (17) 39 (24) 1.57 (0.95-2.57) 0.08 ---  
Other microbe (n=12) 5 (2) 7 (4) 2.10 (0.66-6.74) 0.21   
Negative/unknown (n=98) 61 (26) 37 (23) 0.86 (0.54-1.37) 0.52   
Initial antimicrobial treatment 
Broad-spectrum [c] (n=79) 34 (14) 45 (28) 2.28 (1.38-3.75) 0.001 3.03 (1.43-6.40) 0.004 
Cephalosporins [d] (n=202) 119 (50) 83 (51) 1.03 (0.69-1.53) 0.89   
Penicillin with staph. effect [e] (n=46) 36 (15) 10 (6) 0.37 (0.18-0.76) 0.004 ---  
Penicillin without staph. effect [f] (n=38) 21 (9) 17 (10) 1.20 (0.61-2.35) 0.60   
Other antimicrobials [g] (n=35) 27 (11) 8 (5) 0.40 (0.18-0.91) 0.020   
Initial pathogen(s) covered by initial 
antimicrobial treatment (n=256/310) 
155 (86) 101 (78) 0.56 (0.31-1.01) 0.05 0.38 (0.18-0.80) 0.011 
Data are no. (column-%) of patients unless otherwise specified. OR, odds ratio. 
[a] Logistic regression analysis (Method: Backward/Likelihood ratio/Akaike information criteria, n=308) 
[b] Likelihood ratio -test 
[c] Carbapenem and Piperacillin-Tazobactam 
[d] Cefadroxil, Cefotaxim, Ceftriaxone, Cefuroxime and Cephalexin 
[e] Cloxacillin, Flucloxacillin and other β-lactamase-stable Penicillin 
[f] Amoxicillin, Benzylpenicillin and Phenoxymethylpenicillin 
[g] Clindamycin, Doxycyclin, Fluoroquinolone, Fusidic Acid, Linezolid, Metronidazole, Cotrimoxazole, Tobramycin and Vancomycin 
results 
 
5.2.2 CLINICAL STABILITY ON 0–3 VERSUS 4–5 DAYS 
To further evaluate the factors associated with time to clinical stability, we 
compared patients who reached clinical stability on days 4–5 (n=111, 28%) 
after the diagnosis of cSSSI to patients with clinical stability reached in 3 
days (n=239, 59%). In univariable analyses, clinical stability on days 4–5 was 
associated with ICU treatment [OR 7.05 (3.15–15.77), p<0.001], bacteraemia 
[OR 3.90 (1.95–7.83), p<0.001], diabetic foot infection [OR 2.47 (1.33– 
4.59), p=0.003], diabetes [OR 2.14 (1.35–3.38), p=0.001], male gender [OR 
2.00 (1.24–3.22), p=0.004] and cellulitis/fasciitis [OR 1.69 (1.07–2.66), 
p=0.024]. In contrast, abscess [OR 0.45 (0.28–0.72), p=0.001] or surgery 
within prior three months [OR 0.50 (0.25–0.98), p=0.039] were the factors 
that were associated with clinical stability within 3 days. 
Of the 52 patients (13%) who stabilized after 5 days, a significant 
proportion had been treated in ICU (48%) or had polymicrobial aetiology 
(37%) – and they were treated on an average with 5.5 different antimicrobials 
during their disease course (Study II, Table 1). 
5.2.3 ASSOCIATION OF TIME TO CLINICAL STABILITY TO OUTCOME 
AND TO THE USE OF RESOURCES 
Patients with late (>3 days) clinical stability were more likely to have their 
initial treatment modified and had longer LOS and antimicrobial treatment 
duration as compared to patients with clinical stability in 3 days – and they 
also had more different antibiotic agents used and clinics visited during their 
disease course (Table 13). 
Table 13 Clinical outcomes and resource use of 402 patients with cSSSI categorized by 









≥4 vs 0-3 days 
Full analysis population (N=402) 239 163 OR (95% CI) p 
Hospitalized again due to cSSSI 
(n=66/391) 
39 (17%) 27 (17%) 1.03 (0.60-1.76) 0.93 [a] 
Initial treatment modification [c] 
(n=116/397) 
37 (16%) 79 (49%) 5.18 (3.25-8.27) <0.001 [a] 
Length of hospital stay, days (n=378), 
median (IQR25, 75) 
7 (4, 13) 20 (12, 37) --- <0.001 [b] 
Duration of antibiotics, days (n=395), 
median (IQR25, 75) 
12 (7, 23) 28 (16, 43) --- <0.001 [b] 
No. of antibiotic courses (n=401), 
mean (SD) 
2.8 (1.4) 4.6 (2.4) --- <0.001 [b] 
No. of clinics during hospital stay 
(n=402), mean (SD) 
1.3 (0.7) 2.1 (1.4) --- <0.001 [b] 
Data are number (%) of patients unless otherwise specified. OR, Odds ratio; IQR, interq. range. 
[a] Pearson’s X 2 –test 
[b] Mann-Whitney U –test 





5.3 COMPARISON OF DIABETICS AND NONDIABETICS 
(STUDY III) 
5.3.1 PATIENT POPULATION 
Of the total 460 patients with cSSSI, the main comparison was performed 
between patients with diabetes (n=119) and without it (n=271). Patients with 
diabetic foot infection (DFI, n=70) were analyzed as a separate group. When 
compared to nondiabetics, diabetics were found to be significantly older 
[mean age 71 (SD 15) versus 64 (20) years, p=0.001], have more often 
chronic renal failure (13% versus 2.2%) or a respiratory disease (13% versus 
6.3%), infection localized in the lower extremity (68% versus 49%, p=0.001) 
or classified as cellulitis (65% versus 43%) and to seek treatment earlier from 
the onset of symptoms (Table 14). In contrast, diabetics were detected to 
have less injection drug abuse (0.8% versus 11%) than nondiabetics (Table 
14). 
5.3.2 ANTIMICROBIAL TREATMENT AND MICROBIOLOGICAL 
DIAGNOSIS 
Initial antimicrobial therapy and initial microbiological aetiology of patients 
with cSSSI are presented in tables 15 and 16, respectively. Initial antibiotic 
agents and pathogens were analyzed between diabetics and nondiabetics in 
the main categories and statistically significant differences were not found 
(Tables 15 and 16). Gram-positive aerobic bacteria accounted for 70% of 
microbiological diagnoses in diabetic patients and 69% in nondiabetics and 
the empirical antibiotic treatment covered the initial bacterial pathogen(s) in 
81% and 86% (p=0.250) of diabetics and nondiabetics, respectively. 
When the total period of antimicrobial treatment was analyzed, broad-
spectrum antibiotic agents were used more often in diabetics than in 
nondiabetics (42% versus 28%, OR 1.83, p=0.008). In multivariable analysis, 
polymicrobial aetiology of infection (OR 3.76, p<0.001), invasive surgery 
within the previous three months (OR 2.79, p=0.001), admission to ICU (OR 
2.65, p=0.001) and bacteraemia (OR 2.55, p=0.002) were the other factors 
associated to use of broad-spectrum therapy at any time during the course of 
treatment. Only character that was found to be inversely associated to broad-
spectrum therapy in multivariate analysis was staphylococcal infection (OR 
0.37, p=0.001). After PS-adjusted analysis, diabetes was the only background 


















Diabetics vs nondiabetics 
OR (95% CI) p [a] 
Male gender 70 (59) 157 (58) 1.04 (0.67-1.61) 0.870 
Age >60 years 93 (78) 149 (55) 2.93 (1.78-4.81) <0.001 
Human immunodeficiency virus infection 3 (3) 4 (1) 1.73 (0.38-7.84) 0.474 
Other disease with immunodeficiency 3 (3) 10 (4) 0.68 (0.18-2.50) 0.554 
Cancer / Malignancy 10 (8) 22 (8) 1.04 (0.48-2.27) 0.925 
Chronic renal failure 15 (13) 6 (2) 6.37 (2.41-16.9) <0.001 
Congestive heart disease 10 (8) 25 (9) 0.90 (0.42-1.94) 0.794 
Liver disease 4 (3) 16 (6) 0.55 (0.18-1.70) 0.295 
Peripheral vascular disease 32 (27) 67 (25) 1.12 (0.69-1.83) 0.651 
Respiratory disease 16 (13) 17 (6) 2.32 (1.13-4.77) 0.019 
Alcohol abuse 6 (5) 25 (9) 0.52 (0.21-1.31) 0.160 
Injection drug abuse 1 (1) 29 (11) 0.07 (0.01-0.53) 0.001 
Hospitalization within previous 3 months 30 (25) 50 (18) 1.49 (0.89-2.49) 0.128 
Invasive surgery within previous 3 months 23 (19) 47 (17) 1.14 (0.66-1.99) 0.638 
Treatment with antibiotics before dg 25 (21) 72 (27) 0.74 (0.44-1.23) 0.242 
Abscess 42 (35) 124 (46) 0.65 (0.41-1.01) 0.054 
Cellulitis/fasciitis 77 (65) 116 (43) 2.45 (1.57-3.83) <0.001 
Post-surgical wound 29 (24) 48 (18) 1.50 (0.89-2.52) 0.128 
Post-traumatic wound 10 (8) 37 (14) 0.58 (0.28-1.21) 0.143 
Number of days between 
symptoms start and 
diagnosis 
<2 days 50 (42) 74 (27) 1.93 (1.23-3.03) 0.004 
2-7 days 53 (45) 139 (51) 0.76 (0.50-1.18) 0.219 
>7 days 16 (13) 50 (18) 0.69 (0.37-1.26) 0.225 
Unknown 0 (0) 8 (3) 0.97 (0.95-0.99) 0.058 
Highest C-reactive protein level 
[n=451, mean (SD)] 
240 (116) 222 (140)  0.056 [b] 
Bacteraemia 18 (15) 34 (13) 1.24 (0.67-2.30) 0.490 
Septic shock 2 (2) 6 (5) 0.76 (0.15-3.80) 0.732 
Admitted to ICU 15 (13) 52 (19) 0.61 (0.33-1.13) 0.113 
Data are number (%) of patients unless otherwise specified. 
[a] Pearson’s X2 –test 

























OR (95% CI) p [a] 
Broad-spectrum [b] 26 (22) 39 (14) 1.67 (0.96-2.91) 0.066 
Cephalosporins [c] 60 (51) 133 (49) 1.07 (0.69-1.64) 0.773 
Other [d] 11 (9) 31 (11) 0.79 (0.38-1.64) 0.529 
Penicillins [e] 12 (10) 29 (11) 0.94 (0.46-1.91) 0.866 
Penicillins with staph. effect [f] 9 (8) 38 (14) 0.50 (0.24-1.08) 0.073 
Data are number (%) of patients unless otherwise specified. 
[a] Pearson’s X2 –test 
[b] Carbapenem and Piperacillin-Tazobactam 
[c] Cefadroxil, Cefotaxim, Ceftriaxone, Cefuroxime and Cephalexin 
[d] Clindamycin, Doxycyclin, Fluoroquinolone, Fusidic Acid, Linezolid, Metronidazole, Cotrimoxazole, 
Tobramycin and Vancomycin 
[e] Amoxicillin, Benzylpenicillin and Phenoxymethylpenicillin 
[f] Cloxacillin, Flucloxacillin and other β-lactamase-stable Penicillin 
 









OR (95% CI) p [a] 
Staphylococci 27 (23) 77 (28) 0.74 (0.45-1.22) 0.239 
     Methicillin-sensitive S. aureus 26 (22) 75 (28)   
     Methicillin-resistant S. aureus 1 (1) 2 (1)   
Streptococci 27 (23) 67 (25) 0.89 (0.54-1.49) 0.665 
     Streptococcus pyogenes 8 (7) 46 (17)   
     Streptococcus agalactiae 4 (3) 2 (1)   
     β-hemolytic streptococci 14 (12) 8 (3)   
     Streptococcus pneumoniae 1 (1) 2 (1)   
     Alfa-hemolytic streptococci 0 (0) 9 (3)   
Gram-negative bacteria 8 (7) 13 (5) 1.43 (0.58-3.55) 0.438 
     Enterobacteriacae 5 (4) 8 (3)   
     Pseudomonas 3 (3) 2 (1)   
     Other gram-negative bacteria 0 (0) 3 (1)   
Other microorganism 3 (3) 10 (4) 0.68 (0.18-2.50) 0.554 
     Anaerobic bacteria 2 (2) 8 (3)   
     Enterococci 1 (1) 2 (1)   
Polymicrobial infections 19 (16) 45 (17) 0.95 (0.53-1.71) 0.875 
     Only Gram-positive bacteria 4 (3) 19 (7)   
     Only Gram-negative bacteria 0 (0) 1 (0)   
     Mixed 15 (13) 25 (9)   
Negative / Unknown 35 (29) 59 (22) 1.50 (0.92-2.44) 0.104 
Data are number (%) of patients unless otherwise specified. 















Diabetics vs nondiabetics 
OR (95% CI) p 
Clinical failure due to cSSSI 
(n=457) 
31 (26) 56 (21) 1.33 (0.81-2.21) 0.262 [a] 
Hospitalized again due to cSSSI 
(n=439) 
16 (13) 38 (14) 0.93 (0.50-1.75) 0.825 [a] 
Mortality in 30 days 
(n=460) 
6 (5) 11 (4) 1.26 (0.45-3.48) 0.662 [a] 
Mortality in 12 months 
(n=451) 
23 (19) 25 (9) 2.35 (1.27-4.34) 0.005 [a] 
Time to clinical stability, days 
(n=402, mean (SD) 
4.1 (3.5) 3.9 (4.2)  0.038 [b] 
Duration of antimicrobial therapy, 
days (n=448, median (IQR25, 75) 
21 (12, 38) 14 (8, 28)  <0.001 [b] 
Number of antibiotic therapy courses 
(n=457, mean (SD) 
3.6 (2.2) 3.3 (1.9)  0.560 [b] 
Length of hospital stay, days 
(n=416, median (IQR25, 75) 
13 (6, 21) 10 (5, 20)  0.090 [b] 
Number of clinics during hospital stay 
(n=460, mean (SD) 
1.7 (1.0) 1.5 (1.0)  0.022 [b] 
Data are number (%) of patients unless otherwise specified. 
[a] Pearson’s X2 –test 
[b] Mann-Whitney U –test 
 
5.3.3 PATIENTS WITH DIABETIC FOOT INFECTION 
When compared to nondiabetics, patients with DFI were observed to have 
more often Gram-negative (13% versus 4.8%; OR 2.93, p=0.014) or 
polymicrobial infections (31% versus 17%; OR 2.30, p=0.005) and broad-
spectrum antimicrobial as initial therapy (30% versus 14%; OR 2.54, 
p=0.002) – and less often staphylococcal infection (13% versus 28%; OR 
0.37, p=0.008). The median duration of antimicrobial treatment (21 versus 
14 days; p=0.005) and hospital stay (14 versus 10 days; p=0.006) were found 
to be longer in patients with DFI than in nondiabetics – nevertheless patients 
with DFI had more recurrences than patients without diabetes (26% versus 







5.4 COMPARISON OF MANAGEMENT PRACTICES 
BETWEEN HELSINKI AND GOTHENBURG (STUDY IV) 
5.4.1 PATIENT POPULATION 
Totally 460 patients were included in the analyses out of which 219 were 
from Helsinki and 241 from Gothenburg (Figure 2). Compared to patients in 
Helsinki, patients in Gothenburg were older [mean (SD) age 63 (19) vs. 59 
(18) years; p=0.0117] and had less often diabetes (32% versus 50%, 
p<0.0001), chronic renal failure (2.9% versus 11%, p=0.0004), respiratory 
disease (5.0% versus 10%, p=0.0273), or a prior hospitalization (14% versus 
23%, p=0.0235; Study IV, Table 1). In contrast, patients in Gothenburg had 
more often congestive heart disease (14% versus 4.6%, p=0.0077) and were 
treated more often with antibiotics before their infection met the cSSSI 
criteria (34% versus 24%, p=0.0293; Study IV, Table 1). 
Bacteraemic infection was more common in Helsinki (18% of patients) 
than in Gothenburg (9.1% of patients, p=0.0102), but statistically significant 
differences were not detected in the other measures of disease severity: WBC 
count, peak CRP level, occurrence of septic shock, and in the need for blood 
pressure support (Study IV, Table 2). Both in Helsinki and Gothenburg, 
patients were categorized to have mainly cellulitis (43% and 41%) or abscess 
(43% and 41%), respectively (Study IV, Table 2). Infections related to 
peripheral vascular disease (16% versus 6.4%, p=0.0208) or pressure ulcers 
(5.4% versus 0.5%, p=0.0022) were more common in Gothenburg, whereas 
postsurgical wound infections (23% versus 12%, p=0.0026) were more 
common in Helsinki (Study IV, Table 2). 
5.4.2 MICROBIOLOGICAL DIAGNOSIS 
Microbiological testing was conducted for 97% and 91% of patients and 
microbiological diagnosis was obtained in 65% and 73% of the patients in 
Helsinki and Gothenburg, respectively. Polymicrobial infections were more 
frequently reported in Helsinki (34%) than in Gothenburg (13%, p<0.0001) 
although in monomicrobial infections the proportions of main pathogens – 
staphylococci (46% versus 50%) and streptococci (33% versus 31%) were 
similar (Study IV, Table 3). 
5.4.3 ANTIMICROBIAL THERAPY 
Initial antimicrobial therapy was analysed between cities in the main 
categories: broad-spectrum, cephalosporins, penicillins, penicillins with 
staphylococcal effect and other antibiotics (Study IV, Table 5). When 
compared to Gothenburg, initial antimicrobial therapy in Helsinki consisted 
results 
 
almost exclusively of cephalosporins (69% versus 31%) and broad-spectrum 
antibiotics (27% versus 12%) whereas penicillins with staphylococcal effect 
(0.0% versus 22%) and without it (0.9% versus 21%) were used more often in 
Gothenburg, respectively (p<0.0001; Study IV, Table 5). Flowcharts of 
antibiotic treatment are presented in figure 4. Initially cultured pathogens 
were covered by initial antimicrobial treatment in 79% and 87% of the 
patients in Helsinki (data available for 184 patients) and Gothenburg (data 
available for 169 patients, p=0.056), respectively. 
The median overall durations of antimicrobial therapy were 29 days in 
Helsinki and 12 days in Gothenburg (p<0.0001) and each patient was treated 
in an average with 4.3 different antibiotics in Helsinki and 2.7 in Gothenburg 
(p<0.0001) (Study IV, Table 4). While on intravenous therapy, initial 
antibiotic treatment was modified to another intravenous drug in 55% and 31 
% of the patients (p<0.0001) and the median time from diagnosis to the first 
modification was 3 and 4 days (p=0.0507) in Helsinki and Gothenburg, 
respectively (Study IV, Table 4). The majority of patients – 77% of the 
patients in Helsinki and 53% in Gothenburg – continued with an (mainly 
oral) antibiotic after hospital discharge (Study IV, Table 5). 
5.4.4 CLINICAL MANAGEMENT AND OUTCOME 
The median LOS was 17 days in Helsinki and 11 days in Gothenburg 
(p<0.0001) and home-based care after discharge was given to 32% and 57% 
of patients (p<0.0001), respectively (Study IV, Table 4). Statistically 
significant difference between cities was detected in the number and the 
distribution of the different departments that the patient visited during the 
hospital stay (Study IV, Table 4 and Figure 1). In Helsinki, 57% of the 
patients visited two or more departments during the hospital stay while in 
Gothenburg 85% of the patients were treated in one department only (Study 
IV, Table 4 and Figure 1). Patients were treated most frequently on a surgical 
ward in Helsinki (64%) and on an infectious disease ward in Gothenburg 
(48%; Study IV, Table 4). Surgical intervention after diagnosis of cSSSI was 
conducted on 64% of patients in Helsinki and on 40% of patients in 
Gothenburg (p<0.0001). The mean time from diagnosis to clinical stability 
was 4.4 days in Helsinki and 3.4 days in Gothenburg (p=0.0204) and 
treatment failure (of any kind) occurred in 37% and 38% of the patients 
(p=0.8430), respectively. Recurrence of infection was detected in 16% of the 
patients in Helsinki and 19% in Gothenburg within 12 months after initial 
discharge (p=0.3776). In comparison to patients in Gothenburg, patients in 
Helsinki had higher mortalities within 30 days (5.5% versus 2.1%, p=0.0326) 






Figure 4 The flow of antibiotics in patients with cSSSI in Helsinki (above) and in Gothenburg 
 (below). The thickness of arrow indicates the number of treatment modifications 
 between the main classes of antimicrobials. The arrows outside the circle pointing 





6.1 CHARASTERISTICS OF CSSSI IN TWO NORDIC 
CITIES (STUDY I) 
High rates of bacteraemia and clinical failure, high number of antibiotic 
treatment modifications – but rare streamlining – was revealed in our 
population-based patient material. The median duration of antimicrobial 
therapy (17 days) in our study was longer when compared both to previous 
observational studies in cSSSI (11–15 days) [44,45,71,155] and to treatment 
guidelines [4,156,158]. Further, the use of broad-spectrum antimicrobial 
therapy was high in comparison to recommendations [4,156,158] and also in 
relation to microbiological findings of this study. 
The REACH study, with similar inclusion criteria as in our study, was 
performed in 2010–2011 in a number of European countries with variable 
incidences of MRSA [44]. The baseline characteristics of patients in REACH 
were very similar to those of our study; both had a male predominance (61% 
in our study and 58% in REACH) and median age was the same (62 years). 
Similarly, only 24% of patients in our study and 22% in REACH had no 
comorbidities and the most common underlying diseases were diabetes (41% 
and 34%) and peripheral vascular disease (29% and 21%), respectively [44]. 
These co-morbidities have been reported as the most common also in other 
real-life studies in patients with cSSSI [43,45-47]. 
However, a notable difference in the proportion of patients with 
bacteremic infection was detected between our study (13%) and REACH 
(6.3%) which cannot be explained by differences in the frequency of blood 
cultures taken (53% of patients in both studies) [44]. The occurrence of 
bacteraemia detected in our study on patients with cSSSI was also higher in 
comparison to previous studies on patients with cellulitis (≤5%) [19,81]. 
Further, the low prevalence of bacteremic cases in many clinical trials on 
patients with cSSSI suggests that many patients with more severe cSSSI have 
not been included [122,139,189]. The presence of bacteraemia is clinically 
important since in our study patients with bacteremic infection reached 
clinical stability significantly later (median 4 versus 3 days), had significantly 
higher clinical failure rate (34% versus 21%), longer total antibiotic treatment 
duration (median 30 versus 19 days), and longer LOS (median 21 versus 12 
days) as compared to patients without bacteraemia. 
Both in the REACH and in our study, Gram-positive bacteria accounted 
for the majority of microbiological diagnoses in patients with cSSSI. In the 
REACH, 70% of microbiological diagnoses were due to Gram-positive 





bacteria in 81% of monomicrobial infections in our study which is consistent 
with proportions of Gram-positive infection (61%–84%) reported also in 
other real-life studies on patients with cSSSI [46,47,71,116,117]. In light of 
this, we were somewhat surprised about the high use of broad-spectrum 
antibiotics (19%) and cephalosporins with Gram-negative coverage (49%) in 
the empirical antibiotic treatment. Further, higher failure rate was detected 
among patients with initial broad-spectrum (37%) or cephalosporin (25%) 
therapy as compared to patients initially treated with penicillins (15%), 
penicillins with staphylococcal effect (14%) or other antibiotics (7.7%, Table 
11) – probably mostly reflecting the phenomenon of “confounding by 
indication”. That is, patients with severe conditions more likely receive broad 
spectrum antimicrobial treatment as compared to patients with an optimistic 
prognosis [190]. 
IDSA guideline suggests empirical treatment coverage for Gram-negative 
(and anaerobic bacteria) mainly in infections associated with diabetic foot, 
peripheral vascular insufficiency, bites, prior contact to health care and in 
necrotizing infections [4]. Although many patients of our study belonged to 
these groups, the majority of patients would not have needed Gram-negative 
coverage because 49% of the microbiologically tested patients had only 
Gram-positive bacteria detected. In our material only 29% of the antibiotics 
used in initial therapy had coverage limited mainly to Gram-positives, which 
is in accordance with the results of REACH (20%) [44] and the American 
study by Jenkins et al. (26%) [71]. 
According to microbiological results, 45% of patients in our study could 
have been treated with or streamlined to narrow spectrum agents since they 
had monomicrobial MSSA, streptococcal, enterococcal or polymicrobial 
Gram-positive infection. However, only 5% of patients had their treatment 
streamlined which did not differ from that in REACH (5.6%) [44]. In our 
study, streamlining was associated with bacteraemia, surgical intervention 
after diagnosis, admission to ICU, and higher CRP level (Table 11). Probably, 
bacteraemia or surgical intervention with deep tissue specimens enabled 
more reliable microbiological diagnosis and therefore led to more frequent 
streamlining among these patients. The low rate of streamlining was 
contradicted by the higher frequency of other treatment modifications. In 
total, initial treatment was modified to another intravenous drug in 39% of 
cases and the median time to initial treatment modification was only 3 days 
(Study I, Figure 1). 
In our study, the total duration of antimicrobial therapy was longer than 
in previous real-life studies (Table 7) and clinical trials (Table 5) on patients 
with cSSSI and guideline recommendation [4], maybe partly explained by the 
high occurrence of bacteraemia and more severe infections. Duration of 
intravenous antimicrobial therapy in this study was comparable to the total 
treatment time in previous studies [44,45,71,155] – resulting in longer LOS in 
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our study (median 13 days) as compared to real-life studies in Europe 
(median 12 days) [44] and in U.S. (median 4–5) [45,71]. Opportunities to an 
earlier switch to oral treatment has been detected also in other European 
studies [155,160,191]. 
Interestingly, the higher peak CRP level was associated with longer LOS 
and total duration of antimicrobial therapy, higher rate of treatment 
modifications, streamlining, and treatment failures (Table 11). Of the 
analysed outcomes, only the risk for recurrence was not associated with the 
maximal CRP level and association with mortality was not statistically 
significant. To the best of our knowledge, studies evaluating CRP in 
connection to cSSSI has not been made previously, except for one 
prospective clinical study on patients with DFI that found no independent 
prognostic effect on treatment failure [69]. 
Clearly higher recurrence-rate (16%) was detected in our study as 
compared to other studies (3.7%–8.6%) [44,71] – possibly explained by the 
longer (12 month) observation period of our study. Higher risk of recurrence 
was associated with presence of co-morbidity and interestingly also with 
longer duration of antimicrobial treatment which suggests that longer 
treatment might not protect from recurrence. Thirty day mortality (4.1%) in 
our study was not different from the mortality reported in REACH (3.4%) 
[44] and in other studies on cSSSI (0.4%–9.0%) [25,43,45,46]. Admission to 
ICU was the only factor associated to higher mortality in 30 days (Study I, 
Table 5). In addition we observed high mortality (12%) within 12 months 
most probably reflecting the severe chronic conditions in the study 
population. 
 
6.2 FACTORS ASSOCIATED WITH TIME TO CLINICAL 
STABILITY IN CSSSI (STUDY II) 
In our study, 59 % of patients had their condition stabilised within 3 days 
after diagnosis, that is, within 72 hours which is suggested by FDA as a new 
primary endpoint for clinical trials in SSSI [129]. Later clinical stability was 
associated with many patient´s baseline conditions and disease 
characteristics – not only with treatment related factors. Further, patients 
with no treatment response within 72 hours had eventually more 
antimicrobial treatment modifications and transfers between departments – 
and longer antimicrobial and in-hospital treatment duration. 
As in our study, diabetes was more common among late responders in 
another retrospective European study on patients with cSSSI [192]. They also 
found patients with more severe disease to have more likely late treatment 
response [192] – also in our study bacteraemia and admission to ICU were 





cellulitis, Bruun et al. found late treatment response to be associated with 
female sex, high body mass index (BMI) and cardiovascular disease [193]. 
Clinical trials on patients with ABSSSI have detected trends toward later 
treatment responses in patients with high age, high BMI, and diabetes 
[133,151-154]. Patients with wound infection were found to have more initial 
treatment failures in studies on patients with cSSSI [194] and with ABSSSI 
[195] which is in line with our findings. As in the study by Bruun et al. on 
patients with cellulitis [193], patients with shorter duration of symptoms 
before diagnosis stabilized later also in our study. This probably reflects the 
natural course of disease, or perhaps, patients with more severe disease seek 
treatment earlier. 
Patients with early clinical stability were compared to those who 
stabilized on days 4–5. The same risk factors for late response (Table 12) 
were all significant also in this analysis except peripheral vascular disease, 
posttraumatic wound and surgical interventions – a tendency towards later 
response was detected among those also. That is, the differences detected 
between patients with early (0–3 days) and late (≥4 days) stability are not 
explained only by the subpopulation of patients with very late stability (≥6 
days) – the patients with the most complicated course of disease. Indeed, this 
suggests indirectly that the ideal time point for evaluation of early treatment 
response might be 48–72 hours, as recommended by FDA [129]. 
The association of early treatment response with post-treatment clinical 
cure has been studied in clinical trials (Table 6) [151,152,154,196] and in 
observational studies [192,193]. In general, patients with early response have 
eventually high cure rate in post-treatment evaluation, but many of the 
patients with early nonresponse have also treatment response at the end of 
treatment. In our study, early responders had shorter median lengths of 
hospital stay (7 versus 21 days) and shorter antimicrobial treatment (12 
versus 28 days) as compared to late responders. The association of early 
treatment response to LOS and duration of antimicrobial treatment are 
consistent with the findings of a previous European study [192] and studies 
from the USA [194,195,197,198]. 
In our study, clinical stability was reached earlier if the empiric 
antimicrobial treatment covered the initial pathogen(s) (Table 12) – this 
suggests that the treatment effect of antimicrobial therapy may be evaluated 
by early response, as recommended by FDA. Due to the dominance of Gram-
positive bacteria (62 % of patients with microbiological diagnosis), low 
proportion of MRSA (1%) and high use of antimicrobials comprising also 
Gram-negative coverage, initial pathogens were covered by empirical 
treatment in the vast majority of our patients (83% of patients with 
microbiological diagnosis). In contrast, Bruun et al. found no correlation 
between discordant initial treatment and early nonresponse in patients with 
cellulitis, but their effective sample size was small – only 13/216 of patients 
discussion 
 
had initial treatment that did not cover the pathogens (mainly β-hemolytic 
streptococci) [193]. Yet, in 34% of patients initial treatment was escalated to 
more broad-spectrum therapy in their study, mostly within 2 days after 
admission [193]. This is in line with our findings (Study I); 34% of patients 
had initial treatment modification other than streamlining and median time 
to modification was 3 days. 
In contrast, initial treatment with a broad-spectrum antibiotic – that is, 
antimicrobial therapy that covers almost all pathogens in our low 
antimicrobial resistance environment – was associated with a late treatment 
response. Similar trends were detected by Garau et al, who observed that 
patients treated with piperacillin-tazobactam or ampicillin-sulbactam were 
less likely to have an early response [192]. Further, in the study by Jenkins et 
al. on hospitalized patients with cellulitis or abscess, two thirds of patients 
received broad-spectrum therapy, but the failure rate was not different 
regardless of spectrum of treatment [71]. Together these data suggest that 
broad spectrum empiric coverage would not guarantee early response but 
might even postpone the treatment response. Naturally, this argument 
cannot be proved by observational retrospective studies. Again, patients with 
severe conditions more likely receive broad spectrum antimicrobial 
treatment as compared to patients with an optimistic prognosis [190]. 
The above findings suggest that background and infection related factors 
ought to be controlled when early treatment response is used for comparison 
of various treatment options. Prospective studies are needed to elucidate 
early response dynamics of different patient groups. Until then, what to do 
for the antibiotic treatment of a patient without treatment response in 48–72 
hours? Referring to the above, if patient is not immediately deteriorating or 
antimicrobial treatment is not clearly discordant, do not rush with treatment 
escalation – at least in patients with risk factors for later clinical stability. 
 
6.3 COMPARISON OF DIABETICS AND NONDIABETICS 
(STUDY III) 
Diabetes is one of the main risk factors for cSSSI which is substantiated by 
that diabetics constituted 37% of patient populations in our and 25%–35% in 
other studies on patients with cSSSI [43-47]. In accordance with previous 
studies on less severe SSSI, in our cSSSI population diabetics were older, had 
more likely infection classified as cellulitis or infection localized into a lower 
extremity, had more often chronic renal failure but less injection drug abuse 
in comparison to nondiabetics [134,135,199,200]. However, time from onset 
of symptoms to diagnosis of cSSSI was shorter in diabetics than in 
nondiabetics. Maybe diabetic patients had been educated to seek treatment 





send more often to hospital evaluation than nondiabetics. No statistically 
significant differences were detected in the objective markers of disease 
severity – maximal CRP level, rate of bacteraemia, septic shock, or admission 
to ICU – between diabetics and nondiabetics. 
Statistically significant differences in the microbiological aetiology 
between diabetics (without DFI) and nondiabetics were not found in our 
study nor in the study of Jenkins et al. on patients with less severe SSSI 
[199]. Gram-positive aerobic bacteria accounted for 70% and 69% of the 
microbiological diagnoses in diabetics and nondiabetics, respectively, which 
is consistent with the study by Jenkins et al. [199] and also to other studies 
on patients with diabetes [201] and cSSSI [44,46,71]. Yet, both in our study 
and in the study by Jenkins et al., broad-spectrum antibiotics were used 
more often in diabetics than in nondiabetics [199]. In our study a trend 
toward more frequent use of broad-spectrum therapy was detected already in 
initial treatment among diabetics (p=0.066, Table 15) but it seemed also that 
the antibiotics were changed to broad-spectrum more often among diabetics 
than in nondiabetics. Interestingly, in the study of Jenkins et al. broad 
spectrum agents were not used more frequently in the empirical antibiotic 
choice but only when the total antimicrobial treatment period was analyzed 
[199]. In Study II we found diabetics to have in the average later treatment 
response than nondiabetics which could be a possible explanation for the 
more frequent treatment escalations among them. 
Our results in cSSSI and those of Jenkins et al in SSSI are in line with the 
IDSA guideline recommendation on antimicrobial treatment covering only S. 
aureus and streptococci in the treatment of a cellulitis or an abscess 
irrespective of the presence of diabetes [4]. Empirical antimicrobial therapy 
covering also Gram-negative (and anaerobic) bacteria is recommended only 
in the most severe forms of SSSI [4] and in patients with DFI for moderate-
to-severe infections [76] (Study III, Figure 1). 
In our study the median total duration of antimicrobial treatment was 
longer in diabetics (21 days) than in nondiabetics (14 days) which was also 
observed in SSSI by Jenkins et al [199]. Interestingly, no difference was 
found in the length of hospital stay between diabetics and nondiabetics. That 
is, the difference in the duration of antimicrobial treatment reflected mainly 
antibiotics prescribed at the time of discharge due to unknown reason longer 
for diabetics than nondiabetics. 
Only 15% of our study population had DFI and on IDSA classification they 
would have been classified as severe since signs of systemic infection were 
required for inclusion [76]. In the analyses, patients with DFI were separated 
from other cSSSI among diabetics and they seemed to differ substantially 
from nondiabetics. In comparison to nondiabetics, patients with DFI had 
more often Gram-negative or polymicrobial but less often staphylococcal 
infection and their treatment was started more often with a broad-spectrum 
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antibiotic. In addition, patients with DFI had more recurrences, longer 
median time of hospital stay and longer total antimicrobial treatment 
duration than nondiabetics. These are characteristics that have been detected 
also in previous studies in DFI [8,57,202,203]. 
 
6.4 COMPARISON OF MANAGEMENT PRACTICES 
BETWEEN HELSINKI AND GOTHENBURG (STUDY IV) 
Remarkable differences in the treatment and management of patients with 
cSSSI were revealed between Helsinki and Gothenburg despite the centers’ 
similar public healthcare structure and low incidence of antimicrobial 
resistance. Patients in Helsinki were predisposed more frequently to 
antimicrobials with Gram-negative coverage, had more treatment 
modifications, longer median duration of antimicrobial therapy and longer 
hospital stay than patients in Gothenburg. In addition, during their hospital 
stay 57% of patients in Helsinki were transferred between departments while 
in Gothenburg 85% of patients were treated in one department, most 
commonly in the department of Infectious Diseases. 
Helsinki and Gothenburg area have near equal number of inhabitants and 
after two-step inclusion process we ended up eventually to final patient 
populations with almost equal size (Helsinki 219 and Gothenburg 241 
patients, Figure 2). In the first step, more patients were identified with 
ICD10-codes in Gothenburg (2151 patients) than in Helsinki (1164 patients). 
This might indicate that in Gothenburg more patients with ICD10-code 
possibly related to SSSI had been hospitalized (or evaluated in emergency 
department). Naturally some differences may have been between cities in the 
practices of diagnostic coding. In total, only 460 (14%) of 3315 patients 
initially identified by ICD10-codes met our criteria for cSSSI probably 
indicating that we have caught the patients with the most severe disease. 
Annual incidence of cSSSI was higher in Gothenburg (11/100’000) than in 
Helsinki (9/100’000) which might reflect that more patients with milder 
disease have been included in Gothenburg than in Helsinki. 
Although we tried to apply strict criteria for patient data collection there 
was some differences in the patient populations between the cities. In both 
cities, patients had a high number of co-morbidities and a male 
predominance but patients in Gothenburg were older than in Helsinki (Study 
IV, Table 1). Of the co-morbidities, diabetes, chronic renal failure and 
respiratory disease were more common among patients in Helsinki but 
congestive heart disease among patients in Gothenburg. In both cities, 
patients were classified to have mainly cellulitis or abscess. Post-surgical 





vascular disease ulcers or infected decubitus ulcers were more prevalent in 
Gothenburg. 
Importantly, no significant differences were found between study groups 
among the objective measures of disease severity like WBC count at the time 
of diagnosis, highest CRP level or in the amount of patients admitted to ICU, 
patients with septic shock or in need for blood pressure support. However, 
blood culture positive infections were twice more common in Helsinki (18% 
of patients) than in Gothenburg (9.1% of patients). 
Gram-positive cocci accounted for the majority of infections, however, in 
Helsinki they were detected more often in conjunction with Gram-negative 
or anaerobic bacteria. The higher prevalence of diabetes and previous 
hospitalization may explain in part the higher proportion of polymicrobial 
infections in Helsinki. Yet, in both cities only 15% of patients had DFI and in 
Study III it was observed that diabetics without DFI and nondiabetics had 
similar microbiological aetiologies of infection. Differences in laboratory 
reporting practices between countries cannot be ruled out either since the 
known risk factors for Gram-negative, anaerobic or polymicrobial infection 
were not that different between the cities. In both cities, the majority of 
microbiological diagnoses were detected by superficial swabs which may 
detect also bacterial colonization. 
Although some differences existed between the cities in the patient and 
disease characteristics, differences out of proportion were observed in 
clinical practices between the study centers. Gram-negative or anaerobic 
bacteria were present only in the minority of patients both in Helsinki (33%) 
and in Gothenburg (18%). However, 96% of patients in Helsinki and 47% in 
Gothenburg had Gram-negative bacteria covered in their initial antimicrobial 
therapy. Even after the first treatment modification – that is, while the 
microbiological results are usually available – 61% of patients in Helsinki and 
33% in Gothenburg had still Gram-negative coverage. Cephalosporin-based 
treatment was significantly more common in Helsinki and explains the main 
part of the more common Gram-negative coverage used in Helsinki whereas 
more penicillin-based therapies (without Gram-negative coverage) were used 
in Gothenburg. The more common cephalosporin use in cSSSI seems to 
reflect the general use of antimicrobials in hospital setting. In nationwide 
statistics in 2011, the use of non-penicillin β-lactam antibiotics (most of 
which were cephalosporins) was five times more common in Finland as 
compared to Sweden [204]. In light of the microbiological results, 
staphylococcal penicillins might have been used more often both empirically 
as well as in streamlining. Experience in open care treatment of SSSI in U.K. 
supports this with almost two fold increase in the use of flucloxacillin within 
10 years and no increase in treatment failures related to it [14]. Furthermore, 
the use of antimicrobials with broader spectrum in Helsinki did not result in 
better coverage of the cultured pathogens with the initial antimicrobial 
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treatment which were 87% and 79% in Gothenburg and Helsinki, 
respectively. 
Significant differences were found between the cities also in the number 
of different departments the patient was treated in, the number of 
antimicrobial treatment modifications and the length of hospital stay. During 
their hospital stay, 57% of patients in Helsinki were treated in more than one 
department while in Gothenburg 85% of patients stayed in one department. 
In Helsinki, patients were treated most frequently in the department of 
Surgery but in Gothenburg in the department of Infectious Diseases. Not 
surprisingly patients in Helsinki had more surgical interventions after 
diagnosis. Infectious disease specialist consultation has been shown to 
improve the treatment of S. aureus -bacteraemia [205], but unexpectedly, it 
was detected to be an independent risk factor for broad-spectrum 
antimicrobial therapy in SSSI [199]. To the best of our knowledge, the effect 
of Infectious disease specialist -based treatment on the outcome of patients 
with cSSSI has not been studied. The number of different antibiotic courses 
used per patient was significantly higher in Helsinki (mean 4.3) than in 
Gothenburg (mean 2.7) and also the time from diagnosis to the first 
antibiotic modification was almost statistically significantly longer in 
Gothenburg (median 4 days) than in Helsinki (3 days, p=0.0507). The longer 
average time to clinical stability in Helsinki (4.4 days) compared to 
Gothenburg (3.4 days) may have had an impact to more frequent antibiotic 
modifications in Helsinki. Possibly more frequent transfer of the patient to 
another department (Study IV, Figure 1) has affected to the earlier and more 
frequent modifications in antibiotic treatment in Helsinki and perhaps 
explains partly the longer lengths of hospital stay and total antimicrobial 
treatment duration also. In addition, patients in Gothenburg had more often 
home-based care after in-hospital treatment which may have enabled earlier 
discharge and led to shorter LOS in Gothenburg. 
The most striking difference was the more than double longer total 
antimicrobial treatment in Helsinki (median 29 days) compared to 
Gothenburg (12 days). The median duration of antimicrobial therapy in 
Helsinki also far exceeds the duration detected in clinical trials (Table 5 and 
6), previous real-life studies (Table 7) and recommended in guidelines (Table 
8) while duration in Gothenburg falls within the range detected in previous 
studies and recommendation in their national guideline. Again, although 
there were differences in patients’ baseline or disease characteristics they 
hardly explain totally the difference in the antimicrobial treatment duration 
between the cities. 
The more Gram-positive oriented antimicrobial treatment with fewer 
modifications and shorter duration in Gothenburg did not have a negative 
association to treatment outcome. On the contrary, the 30-day mortality was 





also reflect the differences in patient material between the cities. The 
mortalities in both cities fall within the range from 0.4% to 9.0% that has 
been previously reported for cSSSI [25,43-46]. No differences between cities 
were detected in the number of total treatment failures or recurrences. 
 
6.5 STRENGTHS AND LIMITATIONS OF STUDIES I–IV 
The major strength of this study was its population based approach which 
was enabled by the high affinity to public health care in the Nordic countries. 
That is, patients with an infection severe enough to be included in our study 
have been treated in public hospitals and we were able to catch all cSSSI 
patients from hospital databases as long as patient had the diagnostic ICD10-
code used in our study. Naturally, we may have missed some patients due to 
coding errors. Population based approach may give comprehensive real-life 
data in contrast to clinical trials in which patients with the most severe 
illness commonly have been excluded and also in contrast to retrospective 
cohort studies gathered from selected hospitals. The data were collected in 
two countries which makes it more generalizable. On the other hand, 
different interpretations of patients’ medical records may have potentially 
biased the study data. This study was also conducted in the area of low 
prevalence of MRSA (2011: Finland 2.8%, Sweden 0.8%) [114,115], ruling out 
one possible confounding factor of antimicrobial treatment. 
However, retrospective real-life design was also the main limitation of our 
study because it led to complete dependence on medical records, not initially 
made for research purposes. In the study II, insufficient recording of local 
signs of infection made it impossible to fully evaluate the patients’ treatment 
response in a manner recommended by FDA [24]. The retrospective nature 
led also to missing data in some parameters. The main reason for missing 
data was the common problem in all SSSI studies: due to low sensitivity of 
bacterial cultures especially in cellulitis microbiological documentation is not 
possible in all patients. To control for the missing microbiological data in the 
study II, multivariable analysis was repeated without the covariate “Initial 
pathogen(s) covered by initial antimicrobial treatment” practically with no 
changes in the results. In addition, microbiological diagnosis was based 
mainly on superficial swabs, which may detect also bacterial colonization in 
addition to causative microbiological agents – although this probably did not 
biased intergroup analyses of the study. 
Furthermore, the phenomenon “confounding by indication” is a source 
for bias in retrospective cohort analyses [190]. In our study that is, patients 
with severe conditions, as compared to patients with an optimistic prognosis, 
probably more likely have received broad-spectrum antimicrobial treatment. 
In the study III, the main results were observed in Propensity-score adjusted 
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(PS) analysis correcting for significant differences between diabetics and 
nondiabetics which may reduce the potential bias associated to retrospective 
analyses [206]. 
The definition of DFI was critical in study III. The classification of 
infection was made by two experienced clinicians who collected the data and 
ended up to similar proportions of DFI between cities (Helsinki 32/219, 
Gothenburg 37/241). In our study, only minority of infections in the lower 
extremities of diabetics were classified as DFI. In theory, the inclusion 
criteria of our study may have allowed patients with diabetes (or peripheral 
arterial disease) with less severe infections of lower extremities to be 
included. Yet, no statistically significant differences were detected between 
patients with DFI and nondiabetics in the level of highest CRP or in the 






7.1 CHARACTERISTICS OF CSSSI IN TWO NORDIC 
CITIES (STUDY I) 
Bacteraemia, treatment failure and recurrences in cSSSI were more common 
in this population based real-life study than in previous non-population 
based studies. Gram-positive bacteria constituted 66% of the microbiological 
diagnoses which indicated that the frequent use of antimicrobials with Gram-
negative coverage was most often unnecessary. Treatment modifications – 
other than streamlining – were frequent and the treatment duration was 
longer than previously reported and recommended in the guidelines. Higher 
maximal CRP level seemed to be associated with worse outcome but further 
studies are needed to evaluate the role of CRP as a prognostic tool in cSSSI. 
This study supports the use of narrow spectrum antibiotic therapy for cSSSI 
patients in Finland and Sweden. 
 
7.2 FACTORS ASSOCIATED WITH TIME TO CLINICAL 
STABILITY IN CSSSI (STUDY II) 
Time to treatment response seemed to depend on several baseline 
characteristics and disease related factors other than treatment related 
factors in this retrospective real-life population-based study. This suggests 
that these factors ought to be controlled when early treatment response is 
used for comparison of various treatment options. Even more importantly, 
these findings might be helpful in clinical practice to reduce unnecessary 
early antimicrobial treatment modifications. Time to treatment response was 
associated with outcome i.e. patients with clinical stability within 3 days were 
less likely to have treatment modifications and had shorter hospital stay and 
shorter antimicrobial treatment than those who stabilized later. 
 
7.3 COMPARISON OF DIABETICS AND NONDIABETICS 
(STUDY III) 
After exclusion of patients with diabetic foot infection, no statistically 
significant differences in the microbiological aetiology of cSSSI was found 
between diabetics and nondiabetics. Yet, diabetics were treated significantly 
more often with broad-spectrum antibiotics covering also Gram-negative and 
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anaerobic bacteria and their antibiotic treatment lasted longer than in 
nondiabetics. These results point out that merely Gram-positive 
antimicrobial coverage is usually enough also in diabetics without DFI. 
 
7.4 COMPARISON OF MANAGEMENT PRACTICES 
BETWEEN HELSINKI AND GOTHENBURG (STUDY IV) 
Striking differences were observed in the management of cSSSI between the 
two Nordic cities with similar public healthcare structure and low prevalence 
of antimicrobial resistance. Unnecessary Gram-negative antimicrobial 
coverage was common in both cities though it was more common in Helsinki. 
Compared to mainly Infectious Disease Specialist guided treatment in 
Gothenburg, the more frequent transfer from one department to another in 
Helsinki was linked to longer antimicrobial therapy and hospital stay and to 
more frequent changes in antimicrobial treatment. This study suggests that 
infectious disease specialist-guided therapy and avoidance of transfers 
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